Hepatitis b antiviral agents

ABSTRACT

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: 
     
       
         
         
             
             
         
       
     
     which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/595,294, filed on Dec. 6, 2017. The entire teachings of the above application are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes for making the compounds.

BACKGROUND OF THE INVENTION

HBV infection remains a major public health problem, affecting approximately 2 billion people worldwide. Among them, 350 million people worldwide and 1.4 million in the US develop a chronic infection, which can lead to chronic persistent hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Every year 500,000 to 1 million people die from the end stage of liver diseases caused by HBV infection.

Despite the availability of a prophylactic HBV vaccine, the burden of chronic HBV infection continues to be a significant unmet worldwide medical problem, due to suboptimal treatment options and sustained rates of new infections in most parts of the developing world.

Current treatments do not provide a cure and are limited to only two classes of agents (interferon and nucleoside analogues/inhibitors of the viral polymerase); drug resistance, low efficacy, and tolerability issues limit their impact. The low cure rates of HBV are attributed at least in part to the presence and persistence of covalently closed circular DNA (cccDNA) in the nucleus of infected hepatocytes. However, persistent suppression of HBV DNA slows liver disease progression and helps to prevent HCC. Current therapy goals for HBV-infected patients are directed to reducing serum HBV DNA to low or undetectable levels, and to ultimately reducing or preventing the development of cirrhosis and HCC.

The HBV is an enveloped, partially double-stranded DNA (dsDNA) virus of the hepadnavirus family (Hepadnaviridae). HBV capsid protein (CP) plays essential roles in HBV replication. The predominant biological function of capsid protein is to act as a structural protein to encapsidate pre-genomic RNA and form immature capsid particles, which spontaneously self-assemble from many copies of core dimers in the cytoplasm. Capsid protein also regulates viral DNA synthesis through different phosphorylation status of its C-terminal phosphorylation sites. Also, capsid protein might facilitate the nuclear translocation of viral relaxed circular genome by means of the nuclear localization signals located in the Arginine-rich domain of the C-terminal region of capsid protein. In the nucleus, as a component of viral cccDNA minichromosome, capsid protein could play a structural and regulatory role in the functionality of cccDNA minichromosomes. Capsid protein also interacts with viral large envelope protein in endoplasmic reticulum (ER) and triggers the release of intact viral particles from hepatocytes.

Capsid related anti-HBV inhibitors have been reported. For example, phenylpropen-amide derivatives, including compounds named AT-61 and AT-130 (Feld J. et al. Antiviral Res. 2007, 76, 168), and a class of thiazolidin-4-ones from Valeant (WO2006/033995), have been shown to inhibit pregenomic RNA (pgRNA) packaging. Heteroaryldihydropyrimi-dines or HAPs were discovered in a tissue culture-based screening (Weber et al., Antiviral Res. 2002, 54, 69). These HAP analogs act as synthetic allosteric activators and are able to induce aberrant capsid formation that leads to degradation of the core protein. A subclass of sulphamoyl-arylamides also shows activity against HBV (WO 2013/006394, WO 2013/096744, and WO 2014184365). It was also shown that the small molecule bis-ANS acts as a molecular ‘wedge’ and interferes with normal capsid-protein geometry and capsid formation (Zlotnick A. et al. J. Virol. 2002, 4848).

There is a need in the art for novel therapeutic agents that treat, ameliorate or prevent HBV infection. Administration of these therapeutic agents to an HBV infected patient, either as monotherapy or in combination with other HBV treatments or ancillary treatments, will lead to significantly improved prognosis, diminished progression of the disease, and enhanced seroconversion rates.

SUMMARY OF THE INVENTION

The present invention relates to novel antiviral compounds, pharmaceutical compositions comprising such compounds, as well as methods to treat or prevent viral (particularly HBV) infection in a subject in need of such therapy with said compounds. Compounds of the present invention inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the life cycle of HBV and are also useful as antiviral agents. In addition, the present invention includes the process for the preparation of the said compounds.

In its principal aspect, the present invention provides a compound of Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

A is optionally substituted aryl or optionally substituted heteroaryl; preferably A is optionally substituted azolyl, optionally substituted pyridyl, or optionally substituted phenyl;

B is selected from the group consisting of hydrogen, halo, CN, optionally substituted —C₁-C₆ alkyl, and optionally substituted —C₃-C₆ cycloalkyl; preferably B is hydrogen or optionally substituted methyl;

X is optionally substituted aryl or optionally substituted heteroaryl; preferably X is optionally substituted phenyl;

Alternatively, B and X are taken together with the carbon atom to which they are attached to form an optionally substituted —C₄-C₁₂ cycloalkenyl or optionally substituted 4- to 12-membered heterocyclic, for example, a —C₄-C₁₂ cycloalkenyl or 4- to 12-membered heterocyclic which is fused with an aryl or heteroaryl ring wherein each ring is optionally further substituted;

Y is optionally substituted aryl or optionally substituted heteroaryl; preferably Y is optionally substituted azolyl, optionally substituted pyridyl, or optionally substituted phenyl;

Z is selected from the group consisting of hydrogen, optionally substituted —C₁-C₁₂ alkyl, optionally substituted —C₂-C₁₂ alkenyl, optionally substituted —C₂-C₁₂ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)NR₁R₂, and —C(O)OR₁;

R₁ and R₂ at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl;

Alternatively, R₁ and R₂ are taken together with the nitrogen atom to which they are attached form an optionally substituted 3- to 12-membered heterocyclic;

R is selected from the group consisting of optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, and optionally substituted —C₂-C₈ alkynyl;

Alternatively, R and Z are taken together with the atoms to which they are attached to form an optionally substituted 4- to 12-membered heterocyclic; and

Alternatively, R and A are taken together with the atoms to which they are attached to form an optionally substituted 5- to 7-membered heterocyclic.

Each preferred group stated above can be taken in combination with one, any or all other preferred groups.

DETAILED DESCRIPTION OF THE INVENTION

In one embodiment of the present invention is a compound of Formula (I) as described above, or a pharmaceutically acceptable salt thereof.

Compounds of Formula (I) can have the stereochemistry shown in Formula (Ia) or Formula (Ib),

In preferred embodiments, compounds of Formula (I) have the stereochemistry shown in Formula (Ia).

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A is an optionally substituted azolyl, optionally substituted pyridyl, or optionally substituted phenyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is hydrogen, optionally substituted —C₁-C₄ alkyl, or optionally substituted —C₃-C₈ cycloalkyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is an optionally substituted methyl; preferably, Z is a methyl optionally substituted with halo, —OR₁₁, or —NR₁₁R₁₂; wherein R₁₁ and R₁₂ at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3-to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is —C(O)NR₁R₂ or —C(O)OR₁.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is optionally substituted —C₂-C₈ alkenyl, or optionally substituted —C₂-C₈ alkynyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is optionally substituted 3- to 8-membered heterocyclic.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted. The preferred substituents include optionally substituted methyl, halo, —CN, ═O, ═NR₁₁, —OR₁₁, and —NR₁₁R₁₂; wherein R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Z is —(CH₂)_(n)OR₁₁, —(CH₂)_(n)OC(O)R₁₁, —(CH₂)_(n)C(O)OR₁₁, —(CH₂)_(n)C(O)NR₁₁R₁₂, —(CH₂)_(n)OC(O)OR₁₁, —(CH₂)_(n)O—C(O)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁C(O)R₁₁, —(CH₂)_(n)NR₁₁C(O)OR₁₁, —(CH₂)_(n)NR₁₁C(O)—NR₁₁R₁₂, —(CH₂)_(n)S(O)R₁₂, —(CH₂)_(n)OS(O)₂R₁₂, —(CH₂)_(n)S(O)₂OR₁₁, —(CH₂)_(n)NR₁₁S(O)₂R₁₂, —(CH₂)_(n)—S(O)₂NR₁₁R₁₂; —(CH₂)_(n)NR₁₁S(O)₂NR₁₁R₁₂; —(CH₂)_(n)OP(O)(OR₁₁)₂, —(CH₂)_(n)P(O)(OR₁₁)₂, —(CH₂)_(n)—NR₁₁P(O)(OR₁₂)₂, or —(CH₂)_(n)P(O)(NR₁₁R₁₂)₂; wherein n is 1, 2, 3, 4, 5, or 6; R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein B is hydrogen.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein B is halo, preferably fluoro.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein B is methyl, optionally substituted with one or more halo, preferably fluoro. In certain embodiments, B is difluoromethyl or trifluoromethyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R is optionally substituted —C₁-C₆ alkyl. In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R is optionally substituted —C₃-C₈ cycloalkyl.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R is selected from methyl, ethyl, difluoromethyl, trifluoromethyl, —CH₂CH₂OR₁₁, —CH₂CH₂NR₁₁R₁₂, —CH₂C(O)R₁₁, and —CH₂C(O)NR₁₁R₁₂.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R is —(CH₂)_(n)OR₁₁, —(CH₂)_(n)OC(O)R₁₁, —(CH₂)_(n)C(O)OR₁₁, —(CH₂)_(n)C(O)NR₁₁R₁₂, —(CH₂)_(n)OC(O)OR₁₁, —(CH₂)_(n)O—C(O)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁C(O)R₁₁, —(CH₂)_(n)NR₁₁C(O)OR₁₁, —(CH₂)_(n)NR₁₁C(O)NR₁₁R₁₂, —(CH₂)_(n)S(O)R₁₂, —(CH₂)_(n)OS(O)₂R₁₂, —(CH₂)_(n)S(O)₂OR₁₁, —(CH₂)_(n)NR₁₁S(O)₂R₁₂, —(CH₂)_(n)S(O)₂—NR₁₁R₁₂; —(CH₂)_(n)NR₁₁S(O)₂NR₁₁R₁₂; —(CH₂)_(n)OP(O)(OR₁₁)₂, —(CH₂)_(n)P(O)(OR₁₁)₂, —(CH₂)_(n)NR₁₁P(O)(OR₁₂)₂, or —(CH₂)_(n)P(O)(NR₁₁R₁₂)₂; wherein n, R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is optionally substituted phenyl. In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is optionally substituted heteroaryl.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein A is optionally substituted thiophenyl, optionally substituted imidazolyl, optionally substituted thiazolyl, optionally substituted oxazolyl, optionally substituted pyridyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Y is optionally substituted phenyl. In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Y is optionally substituted heteroaryl. In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein Y is optionally substituted azolyl or optionally substituted pyridyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is optionally substituted phenyl; and Y is an optionally substituted heteroaryl. In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is optionally substituted phenyl; and Y is optionally substituted azolyl, optionally substituted pyridyl, or optionally substituted phenyl.

In certain embodiments, the present invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein X is optionally substituted monocyclic heteroaryl; and Y is optionally substituted azolyl, optionally substituted pyridyl, or optionally substituted phenyl.

In another particular embodiment, the present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein A and X are each independently an aryl or heteroaryl group derived from one of the following by removal of one hydrogen atom:

wherein each of the above shown aryl and heteroaryl groups is optionally substituted and is preferably connected to the dihydropyrimidine core through a carbon atom.

In another particular embodiment, the present invention relates to compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein at least one of A and X is an aryl or heteroaryl group derived from one of the following by removal of one hydrogen atom:

wherein each of the above shown aryl and heteroaryl groups is optionally substituted and is preferably connected to the dihydropyrimidine core through a carbon atom.

In certain embodiments, A and X are each independently selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted. The preferred substituents are optionally substituted methyl, halo, CN, OR₁₁, and —NR₁₁R₁₂; wherein R and R₁₂ are as previously defined.

In certain embodiments, at least one of A and X is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted when possible. The preferred substituents are optionally substituted methyl, halo, CN, OR₁₁, or —NR₁₁R₁₂; wherein R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Y is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted. The preferred substituents include optionally substituted methyl, halo, —CN, —OR₁₁, and —NR₁₁R₁₂; wherein R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Y is optionally substituted azolyl.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Y is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted when possible.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Y is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted. The preferred substituents include optionally substituted —C₁-C₄-alkyl, halo, —CN, —OR₁₁, and —NR₁₁R₁₂; R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Y is selected from the groups set forth below:

wherein R₂₀ is R₁₁ as defined above. Preferably, optionally substituted C₁-C₄-alkyl or C₃-C₆-cycloalkyl. More preferably, R₂₀ is optionally substituted methyl or optionally substituted cyclopropyl. In certain embodiments, R₂₀ is difluoromethyl, trifluoromethyl, cyclopropyl or 2,2,2-trifluoroethyl.

In certain embodiments, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is —(CH₂)_(n′)-M; wherein n′ is 1, 2, or 3; M is hydrogen, —OR₁₁, protected hydroxy, —CR₁₁R₁₂R₃, —NR₁₁R₁₂, protected amino or selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted; the preferred substituents include halo, ═O, ═NR₁₁, —OR₁₁, —NR₁₁R₁₂, —CN, —CO₂R₁₁, —C(O)NR₁₁R₁₂, and optionally substituted methyl; R₃ is selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, —CN, —OR₁₁, and —NR₁₁R₁₂; R₄ is selected from the group consisting of —NR₁₁R₁₂, OR₁₁, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃—C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; R₅ is selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)R₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —S(O)₂R₁₁, —S(O)₂NR₁₁R₁₂, —C(O)NR₁₁S(O)₂R₁₂; G is independently selected from CR₁₁R₁₂, O and NR₅; G′ is independently selected from CR₅ and N; and n′, R₁₁ and R₁₂ are as previously defined. In certain embodiments, R₅ is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted; the preferred substituents include halo, —OR₁₁, —NR₁₁R₁₂, —NR₁₁R₁₂, —CN, —CO₂R₁₁, —C(O)NR₁₁R₁₂, optionally substituted methyl, and optionally substituted phenyl. In another embodiment, R₅ is —SO₂NH₂.

In another embodiment, the present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Z is —(CH₂)_(n′)-M, preferably —CH₂-M, wherein M is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted when possible; the preferred substituents include halo, —OR₁₁, —NR₁₁R₁₂, —CN, —CO₂R₁₁, —C(O)NR₁₁R₁₂, optionally substituted methyl, and optionally substituted phenyl; m′ is 1, 2, or 3; and n′, R₁₁, R₁₂, and R₅ are as previously defined.

In another embodiment, the compound of Formula (I) is represented by Formula (IIa) or (IIb) or a pharmaceutically acceptable salt thereof:

wherein A₁ is a optionally substituted 5-membered heteroaryl group containing 1 to 4 heteroatoms selected from O, N, and S; preferably A₁ is an optionally substituted azole group including but not limited to pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl; each optionally substituted; A₂ is an optionally substituted phenyl, thiophenyl or 6-membered heteroaryl group including but not limited to pyridinyl, pyrazinyl, or pyrimidinyl; each optionally substituted; B, R, X, Y, and Z are as previously defined.

In another embodiment, the compound of Formula (I) is represented by Formula (IIa-1) or (IIb-1), or a pharmaceutically acceptable salt thereof:

wherein X₁ is optionally substituted methyl, halo, CN, OR₁₁, or NR₁₁R₁₂; m is 0, 1, 2, 3, 4 or 5; A₁, A₂, R, Y, Z, R₁₁, and R₁₂ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (Ha-1) or (IIb-1), or a pharmaceutically acceptable salt thereof, wherein m is 0 or m is 1-5 and each X₁ is halo. In certain embodiments, the compound of Formula (I) is represented by Formula (IIa-1) or (IIb-1), or a pharmaceutically acceptable salt thereof, wherein Y is optionally substituted azolyl. In another embodiment, the compound of Formula (I) is represented by Formula (IIa-1) or (IIb-1), or a pharmaceutically acceptable salt thereof, wherein Z is hydrogen or optionally substituted methyl.

In certain embodiments, the compound of Formula (I) is represented by Formula (Ha-1) or (IIb-1), or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of —(CH₂)_(n)OR₁₁, —(CH₂)_(n)OC(O)R₁₁, —(CH₂)_(n)C(O)OR₁₁, —(CH₂)_(n)C(O)NR₁₁R₁₂, —(CH₂)_(n)OC(O)OR₁₁, —(CH₂)_(n)O—C(O)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁R₁₂, —(CH₂)_(n)NR₁IC(O)R₁₁, —(CH₂)_(n)NR₁₁C(O)OR₁₁, —(CH₂)_(n)NR₁₁C(O)NR₁₁R₁₂, —(CH₂)_(n)S(O)R₁₂, —(CH₂)_(n)OS(O)₂R₁₂, —(CH₂)_(n)S(O)₂OR₁₁, —(CH₂)_(n)NR₁₁S(O)₂R₁₂, —(CH₂)_(n)S(O)₂NR₁₁R₁₂; —(CH₂)_(n)NR₁₁S(O)₂NR₁₁R₁₂; —(CH₂)_(n)OP(O)(OR₁₁)₂, —(CH₂)_(n)P(O)(OR₁₁)₂, —(CH₂)_(n)NR₁₁P(O)—(OR₁₂)₂, and —(CH₂)_(n)P(O)(NR₁₁R₁₂)₂; preferably, R is —(CH₂)_(n)OR₁₁; and n, R₁₁ and R₁₂ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (Ha-1) or (IIb-1), or a pharmaceutically acceptable salt thereof, wherein Z is selected from the group consisting of —(CH₂)_(n)OR₁₁, —(CH₂)_(n)OC(O)R₁₁, —(CH₂)_(n)C(O)OR₁₁, —(CH₂)_(n)C(O)NR₁₁R₁₂—(CH₂)_(n)OC(O)OR₁₁, —(CH₂)_(n)O—C(O)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁C(O)R₁₁, —(CH₂)_(n)NR₁₁C(O)OR₁₁, —(CH₂)_(n)NR₁₁C(O)NR₁₁R₁₂, —(CH₂)_(n)S(O)R₁₂, —(CH₂)_(n)OS(O)₂R₁₂, —(CH₂)_(n)S(O)₂OR₁₁, —(CH₂)_(n)NR₁₁S(O)₂R₁₂, —(CH₂)_(n)S(O)₂NR₁₁R₁₂; —(CH₂)_(n)NR₁₁S(O)₂NR₁₁R₁₂; —(CH₂)_(n)OP(O)(OR₁₁)₂, —(CH₂)_(n)P(O)(OR₁₁)₂, —(CH₂)_(n)NR₁₁P(O)—(OR₁₂)₂, and —(CH₂)_(n)P(O)(NR₁₁R₁₂)₂; preferably, Z is —(CH₂)_(n)NR₁₁S(O)₂R₁₂; and n, R₁₁ and R₁₂ are as previously defined.

In another embodiment, the compound of Formula (I) is represented by Formula (IIa-2), or (IIb-2), or a pharmaceutically acceptable salt thereof:

wherein X₁, m, A₁, A₂, R, Y, M, R₃, R₁₁ and R₁₂ are as previously defined.

In another embodiment, the compound of Formula (I) is represented by Formula (IIa-2) or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein M is —CR₁₁R₁₂R₃, or —NR₁₁R₁₂; wherein R₁₁ and R₁₂ are taken together with the atom to which they are attached to form an optionally substituted C₃-C₈ mono-cycloalkyl or an optionally substituted 3- to 8-membered mono-heterocyclic, wherein said cycloalkyl or heterocyclic contains 0 to 3 substituents independently selected from ═CR₁₃R₁₄, ═O, and ═NR₁₃; R₁₃ and R₁₄ are each independently selected from the group consisting of hydrogen, halo, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; alternatively, R₁₃ and R₁₄ are taken together with the carbon atom to which they are attached to form an optionally substituted C₃-C₈ cycloalkyl; R₃ is as previously defined.

In yet another embodiment, the compound of Formula (I) is represented by Formula (IIa-2) or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein M is —CR_(11′)R_(12′)R₃, or —NR_(11′)R_(12′); wherein R_(11′) and R_(12′) are taken together with the atom they are attached to form an optionally substituted C₅-C₁₂ bi- or tri-cycloalkyl or an optionally substituted 5- to 12-membered bi- or tri-heterocyclic, wherein said optionally substituted C₅-C₁₂ bi- or tri-cycloalkyl or an optionally substituted 5- to 12-membered bi- or tri-heterocyclic comprises a first ring which includes the carbon atom to which R_(11′), R_(12′) and R₃ are attached or the nitrogen atom to which R_(11′) and R_(12′) are attached, a second ring and an optional third ring, wherein the second ring is (1) spiro attached to the first ring, (2) fused to the first ring or (3) formed by a 1,3- or 1,4-bridging group between two ring atoms of the first ring. Preferably, the first ring is a 3-, 4-, 5-, 6- or 7-membered ring. R₃ is as previously defined.

In yet another embodiment, the compound of Formula (I) is represented by Formula (IIa-2) or (IIb-2), or a pharmaceutically acceptable salt thereof, wherein R is selected from the group consisting of —(CH₂)_(n)OR₁₁, —(CH₂)_(n)OC(O)R₁₁, —(CH₂)_(n)C(O)OR₁₁, —(CH₂)_(n)C(O)—NR₁₁R₁₂, —(CH₂)_(n)OC(O)OR₁₁, —(CH₂)_(n)O—C(O)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁R₁₂, —(CH₂)_(n)NR₁₁C(O)R₁₁, —(CH₂)_(n)NR₁₁C(O)OR₁₁, —(CH₂)_(n)NR₁₁C(O)NR₁₁R₁₂, —(CH₂)_(n)S(O)R₁₂, —(CH₂)_(n)OS(O)₂R₁₂, —(CH₂)_(n)S(O)₂OR₁₁, —(CH₂)_(n)NR₁₁S(O)₂R₁₂, —(CH₂)_(n)S(O)₂NR₁₁R₁₂; —(CH₂)_(n)NR₁₁S(O)₂NR₁₁R₁₂; —(CH₂)_(n)OP(O)(OR₁₁)₂, —(CH₂)_(n)P(O)(OR₁₁)₂, —(CH₂)_(n)NR₁₁P(O)(OR₁₂)₂, and —(CH₂)_(n)P(O)—(NR₁₁R₁₂)₂; n, R₁₁ and R₁₂ are as previously defined.

In another embodiment, the compound of Formula (I) is represented by Formula (IIa-3) or (IIb-3), or a pharmaceutically acceptable salt thereof:

wherein E at each occurrence is the same or different and independently selected from —CR₁₅R₁₆—, —C(O)—, —O—, —NR₁₆—, —S—, and —S(O)₂—; u is 0, 1, 2, or 3; R₁₅ is hydrogen, halo, CN, —NR₁₁R₁₂, —N₃, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; R₁₆ is hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; v is 0, 1, 2, 3, or 4; X₁, A₁, A₂, R, Y, Z, R₁₁, and R₁₂ are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (IIa-3) or (IIb-3) and pharmaceutically acceptable salts thereof, wherein two vicinal E groups are taken together to form an optionally substituted C═C double-bond or an optionally substituted fused ring. In certain embodiments, two non-adjacent E groups are taken together to form a bridging group.

In another embodiment, the compound of Formula (I) is represented by Formula (IIIa) or (IIIb), or a pharmaceutically acceptable salt thereof,

wherein u, B, X, A₁, A₂, Y, and E, are as previously defined.

In certain embodiments, the present invention relates to compounds of Formula (IIIa) or (IIIb) and pharmaceutically acceptable salts thereof, wherein two vicinal E groups are taken together to form a C═C double-bond, a C═N double-bond or a fused ring.

In certain embodiments, the present invention relates to compounds of Formula (IIIa) or (IIIb) or pharmaceutically acceptable salts thereof, wherein

is selected from the groups set forth below:

is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted; the preferred substituents include halo, —OR₁₁, —NR₁₁R₁₂, —CN, —CO₂R₁₁, —C(O)NR₁₁R₁₂, optionally substituted methyl, and optionally substituted phenyl; and R₁₁, R₁₂, R₃, R₅, and m′ are as previously defined. Alternatively, R₅ and R₁₁ are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic. More preferably, R₅ is selected from the groups set forth below:

wherein each of the above shown groups is optionally substituted when possible; the preferred substituents include halo, —OR₁₁, —NR₁₁R₁₂, —CN, —CO₂R₁₁, —C(O)NR₁₁R₁₂, optionally substituted methyl, and optionally substituted phenyl. In another embodiment, R₅ is —SO₂NH₂. In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-1) or (IIIb-1), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, B, Y, E, and u are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-2) or (IIIb-2), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, Y, E, and u are as previously defined.

In certain embodiment, the compound of Formula (I) is represented by Formula (IIIa-3) or (IIIb-3), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, Y, E, and u are as previously defined.

In certain embodiment, the compound of Formula (I) is represented by Formula (IIIa-4) or (IIIb-4), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, Y, R₅ and R₁₁ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-4) or (IIIb-4), or a pharmaceutically acceptable salt thereof, wherein A₁, A₂, X₁, m, R₅ and R₁₁ are as previously defined, and Y is optionally substituted azolyl. Preferably Y is optionally substituted pyrazolyl or oxazolyl.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-5) or (IIIb-5), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, Y, R₅ and R₁₁ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-5) or (IIIb-5), or a pharmaceutically acceptable salt thereof, wherein A₁, A₂, X₁, m, R₅ and R₁₁ are as previously defined, and Y is optionally substituted azolyl. Preferably Y is optionally substituted pyrazolyl or oxazolyl.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-6) or (IIIb-6), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, Y, R₅ and R₁₁ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-6) or (IIIb-6), or a pharmaceutically acceptable salt thereof, wherein A₁, A₂, X₁, m, R₅ and R₁₁ are as previously defined, and Y is optionally substituted azolyl. Preferably Y is optionally substituted pyrazolyl or oxazolyl.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-7), (IIIb-7), (IIIc-7), or (IIId-7), or a pharmaceutically acceptable salt thereof,

wherein A₁, A₂, X₁, m, R₅, R₁₁ and R₂₀ are as previously defined.

In certain embodiments, the compound of Formula (I) is represented by Formula (IIIa-8) or (IIIb-8), or a pharmaceutically acceptable salt thereof,

wherein R₅, R₁₁ and R₂₀ are as previously defined.

In certain embodiments of the compounds of Formulae (IIIc-7), (IIId-7), and (IIIb-8), R₂₀ is not methyl. In other embodiments of the compounds of Formulae (IIIc-7), (IIId-7), and (IIIb-8), R₂₀ is not methyl, ethyl or difluoromethyl.

In certain embodiments of the compounds of Formulae (IIIa-7), (IIIb-7) and (IIIa-8), R₂₀ is difluoromethyl, cyclopropyl, isopropyl, trifluoromethyl or 2,2,2-trifluoroethyl. In certain embodiments of the compounds of Formulae (IIIa-7), (IIIb-7) and (IIIa-8), R₂₀ is methyl, ethyl, or difluoromethyl. In certain embodiments of the compounds of Formulae (IIIa-7), (IIIb-7) and (IIIa-8), R₂₀ is difluoromethyl. In one embodiment, the compounds of the invention do not include the compound of Formula (IIIa-8) where R₂₀ is methyl, R₁₁ is hydrogen and R₅ is —S(O)₂-cyclopropyl.

In another embodiment, the compound of Formula (I) is represented by Formula (IV), or a pharmaceutically acceptable salt thereof,

wherein, B, X, Y, Z, E and u are as previously defined.

In yet another embodiment, the compound of Formula (I) is represented by Formula (IVa) (IVb), (IVc), or a pharmaceutically acceptable salt thereof,

wherein each T is independently —CR₁₅, or N; X₁, m, Y, Z, E, u, and R₁₅ are as previously defined. Preferably R₁₅ is H, halo, methyl or CF₃.

In certain embodiments, the compound of Formula (I) is represented by Formula (Va) or (Vb), or a pharmaceutically acceptable salt thereof,

wherein X₂ at each occurrence is independently selected from hydrogen or halogen; W is selected from the group consisting of hydrogen, halogen, CN, —N₃, —OR₁₁, —CR₁₁R₁₂R₃, —NR₁₁R₁₂, protected hydroxy, protected amino, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)R₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —S(O)₂R₁₁, —S(O)₂NR₁₁R₁₂, —NR₁₁S(O)₂R₁₂, —NR₁₁S(O)₂NR₁₁R₁₂, —P(O)(OR₁₁)₂, and —NR₁₁P(O)(OR₁₁)₂; R₃, R₁₅, R₁₁ and R₁₂ are as previously defined.

In an embodiment, the present invention relates to compounds of Formula (Va) and (Vb), and pharmaceutically acceptable salts thereof, wherein W is selected from the group consisting of hydrogen, halogen, CN, —N₃, —OR₁₁, —NR₁₁R₁₂, protected hydroxy, and protected amino; and R₁₅ is optionally substituted —C₁-C₈ alkyl.

In certain embodiments, the compounds of the invention do not include the compounds set forth below or pharmaceutically acceptable salts thereof:

It will be appreciated that the description of the present invention herein should be construed in congruity with the laws and principles of chemical bonding. In some instances, it may be necessary to remove a hydrogen atom in order to accommodate a substituent at any given location.

It will be yet appreciated that the compounds of the present invention may contain one or more asymmetric carbon atoms and may exist in racemic, diastereoisomeric, and optically active forms. It will still be appreciated that certain compounds of the present invention may exist in different tautomeric forms. All tautomers are contemplated to be within the scope of the present invention.

In one aspect, the compounds of the invention are useful in HBV treatment by disrupting, accelerating, reducing, delaying and/or inhibiting normal viral capsid assembly and/or disassembly of immature or mature particles, thereby inducing aberrant capsid morphology and leading to antiviral effects such as disruption of virion assembly and/or disassembly, virion maturation, and/or virus egress. In one embodiment, a disruptor of capsid assembly interacts with mature or immature viral capsid to perturb the stability of the capsid, thus affecting assembly and/or disassembly. In another embodiment, a disruptor of capsid assembly perturbs protein folding and/or salt bridges required for stability, function and/or normal morphology of the viral capsid, thereby disrupting and/or accelerating capsid assembly and/or disassembly. In yet another embodiment, the compounds of the invention bind capsid and alter metabolism of cellular polyproteins and precursors, leading to abnormal accumulation of protein monomers and/or oligomers and/or abnormal particles, which causes cellular toxicity and death of infected cells. In another embodiment, the compounds of the invention cause failure of the formation of capsid of optimal stability, affecting efficient uncoating and/or disassembly of viruses (e.g., during infectivity).

In one embodiment, the compounds of the invention disrupt and/or accelerate capsid assembly and/or disassembly when the capsid protein is immature. In another embodiment, the compounds of the invention disrupt and/or accelerate capsid assembly and/or disassembly when the capsid protein is mature. In yet another embodiment, the compounds of the invention disrupt and/or accelerate capsid assembly and/or disassembly during vial infectivity. In yet another embodiment, the disruption and/or acceleration of capsid assembly and/or disassembly attenuates HBV viral infectivity and/or reduces viral load. In yet another embodiment, disruption, acceleration, inhibition, delay and/or reduction of capsid assembly and/or disassembly eradicates the virus from the host organism. In yet another embodiment, eradication of the HBV from a host advantageously obviates the need for chronic long-term therapy and/or reduces the duration of long-term therapy.

In one embodiment, the compounds described herein are suitable for monotherapy and are effective against natural or native HBV strains and against HBV strains resistant to currently known drugs. In another embodiment, the compounds described herein are suitable for use in combination therapy.

In another embodiment, the compounds of the invention can be used in methods of modulating (e.g., inhibit, disrupt or accelerate) the activity of HBV cccDNA. In yet another embodiment, the compounds of the invention can be used in methods of diminishing or preventing the formation of HBV cccDNA. In another embodiment, the additional therapeutic agent is selected from core inhibitor, which includes GLS4, GLS4JHS, JNJ-379, ABI-H0731, ABI-H2158, AB-423, AB-506, WX-066, and QL-OA6A; immune modulator or immune stimulator therapies, which includes T-cell response activator AIC649 and biological agents belonging to the interferon class, such as interferon alpha 2a or 2b or modified interferons such as pegylated interferon, alpha 2a, alpha 2b, lamda; or STING (stimulator of interferon genes) modulator; or TLR modulators such as TLR-7 agonists, TLR-8 agonists or TLR-9 agonists; or therapeutic vaccines to stimulate an HBV-specific immune response such as virus-like particles composed of HBcAg and HBsAg, immune complexes of HBsAg and HBsAb, or recombinant proteins comprising HBx, HBsAg and HBcAg in the context of a yeast vector; or immunity activator such as SB-9200 of certain cellular viral RNA sensors such as RIG-I, NOD2, and MDA5 protein, or RNA interence (RNAi) or small interfering RNA (siRNA) such as ARC-520, ARC-521, ARO-HBV, ARB-1467, and ALN-HBV RNAi, or antiviral agents that block viral entry or maturation or target the HBV polymerase such as nucleoside or nucleotide or non-nucleos(t)ide polymerase inhibitors, and agents of distinct or unknown mechanism including agents that disrupt the function of other essential viral protein(s) or host proteins required for HBV replication or persistence such as REP 2139, RG7834, and AB-452. In an embodiment of the combination therapy, the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Aba-cavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, PMPA, cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine.

In another embodiment of the combination therapy, the TLR-7 agonist is selected from the group consisting of SM360320 (9-benzyl-8-hydroxy-2-(2-methoxy-ethoxy)ad-enine), AZD 8848 (methyl [3-({[3-(6-amino-2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl)propyl][3-(4-morpholinyl) propyl] amino Imethyl)phenyl] acetate), GS-9620 (4-Amino-2-butoxy-8-[3-(1-pyrrolidinylmethyl)benzyl]-7,8-dihydro-6(5H)-pteridinone), AL-034 (TQ-A₃₃₃₄), and RO6864018.

In another embodiment of the combination therapy, the TLR-8 agonist is GS-9688.

In an embodiment of these combination therapies, the compound and the additional therapeutic agent are co-formulated. In another embodiment, the compound and the additional therapeutic agent are co-administered.

In another embodiment of the combination therapy, administering the compound of the invention allows for administering of the additional therapeutic agent at a lower dose or frequency as compared to the administering of the at least one additional therapeutic agent alone that is required to achieve similar results in prophylactically treating an HBV infection in an individual in need thereof.

In another embodiment of the combination therapy, before administering the therapeutically effective amount of the compound of the invention, the individual is known to be refractory to a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, antiviral compounds of distinct or unknown mechanism, and combination thereof.

In still another embodiment of the method, administering the compound of the invention reduces viral load in the individual to a greater extent compared to the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, antiviral compounds of distinct or unknown mechanism, and combination thereof.

In another embodiment, administering of the compound of the invention causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, antiviral compounds of distinct or unknown mechanism, and combination thereof.

It should be understood that the compounds encompassed by the present invention are those that are suitably stable for use as pharmaceutical agent.

Definitions

Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.

The term “aryl,” as used herein, refers to a mono- or polycyclic carbocyclic ring system comprising at least one aromatic ring, including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, and indenyl. A polycyclic aryl is a polycyclic ring system that comprises at least one aromatic ring. Polycyclic aryls can comprise fused rings, covalently attached rings or a combination thereof.

The term “heteroaryl,” as used herein, refers to a mono- or polycyclic aromatic radical having one or more ring atom selected from S, O and N; and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzoxazolyl, quinoxalinyl. A polycyclic heteroaryl can comprise fused rings, covalently attached rings or a combination thereof.

In accordance with the invention, aromatic groups can be substituted or unsubstituted.

The term “azole group,” as used herein, refers to 5-membered heteroaromatic ring containing at least one nitrogen atom. Preferred azole groups contain a nitrogen atom and at least one additional heteroatom, preferably a nitrogen, oxygen or sulfur atom. Azole groups include, but are not limited to pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl. An azole group is termed “ortho” substituted in reference to two substituents which are on adjacent ring atoms. An azole group is termed “meta” substituted in reference to two substituents which are not on adjacent ring positions.

The term “alkyl” as used herein, refers to saturated, straight- or branched-chain hydrocarbon radicals. “C₁-C₄ alkyl,” “C₁-C₆ alkyl,” “C₁-C₈ alkyl,” “C₁-C₁₂ alkyl,” “C₂-C₄ alkyl,” or “C₃-C₆ alkyl,” refer to alkyl groups containing from one to four, one to six, one to eight, one to twelve, 2 to 4 and 3 to 6 carbon atoms respectively. Examples of C₁-C₈ alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, heptyl and octyl radicals.

The term “alkenyl” as used herein, refers to straight- or branched-chain hydrocarbon radicals having at least one carbon-carbon double bond by the removal of a single hydrogen atom. “C₂-C₈ alkenyl,” “C₂-C₁₂ alkenyl,” “C₂-C₄ alkenyl,” “C₃-C₄ alkenyl,” or “C₃-C₆ alkenyl,” refer to alkenyl groups containing from two to eight, two to twelve, two to four, three to four or three to six carbon atoms respectively. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, heptenyl, octenyl, and the like.

The term “alkynyl” as used herein, refers to straight- or branched-chain hydrocarbon radicals having at least one carbon-carbon double bond by the removal of a single hydrogen atom. “C₂-C₈ alkynyl,” “C₂-C₁₂ alkynyl,” “C₂-C₄ alkynyl,” “C₃-C₄ alkynyl,” or “C₃-C₆ alkynyl,” refer to alkynyl groups containing from two to eight, two to twelve, two to four, three to four or three to six carbon atoms respectively. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.

The term “cycloalkyl”, as used herein, refers to a monocyclic or polycyclic saturated carbocyclic ring or a bi- or tri-cyclic group fused, bridged or spiro system, and the carbon atoms may be optionally oxo-substituted or optionally substituted with exocyclic olefinic double bond. Preferred cycloalkyl groups include C₃-C₁₂ cycloalkyl, C₃-C₆ cycloalkyl, C₃-C₈ cycloalkyl and C₄-C₇ cycloalkyl. Examples of C₃-C₁₂ cycloalkyl include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl, cyclooctyl, 4-methylene-cyclohexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.0]hexyl, spiro[2.5]octyl, 3-methylenebicyclo[3.2.1]octyl, spiro[4.4]nonanyl, and the like.

The term “cycloalkenyl”, as used herein, refers to monocyclic or polycyclic carbocyclic ring or a bi- or tri-cyclic group fused, bridged or spiro system having at least one carbon-carbon double bond and the carbon atoms may be optionally oxo-substituted or optionally substituted with exocyclic olefinic double bond. Preferred cycloalkenyl groups include C₃-C₁₂ cycloalkenyl, C₃-C₈ cycloalkenyl or C₅-C₇ cycloalkenyl groups. Examples of C₃-C₁₂ cycloalkenyl include, but not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, bicyclo[2.2.1]hept-2-enyl, bicyclo[3.1.0]hex-2-enyl, spiro[2.5]oct-4-enyl, spiro[4.4]non-1-enyl, bicyclo[4.2.1]non-3-en-9-yl, and the like.

As used herein, the term “arylalkyl” means a functional group wherein an alkylene chain is attached to an aryl group, e.g., —CH₂CH₂-phenyl. The term “substituted arylalkyl” means an arylalkyl functional group in which the aryl group is substituted. Similarly, the term “heteroarylalkyl” means a functional group wherein an alkylene chain is attached to a heteroaryl group. The term “substituted heteroarylalkyl” means a heteroarylalkyl functional group in which the heteroaryl group is substituted.

As used herein, the term “alkoxy” employed alone or in combination with other terms means, unless otherwise stated, an alkyl group having the designated number of carbon atoms connected to the rest of the molecule via an oxygen atom, such as, for example, methoxy, ethoxy, 1-propoxy, 2-propoxy (isopropoxy) and the higher homologs and isomers. Preferred alkoxy are (C₁-C₃) alkoxy.

It is understood that any alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic and cycloalkenyl moiety described herein can also be an aliphatic group or an alicyclic group.

An “aliphatic” group is a non-aromatic moiety comprised of any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contains one or more units of unsaturation, e.g., double and/or triple bonds.

Examples of aliphatic groups are functional groups, such as alkyl, alkenyl, alkynyl, O, OH, NH, NH₂, C(O), S(O)₂, C(O)O, C(O)NH, OC(O)O, OC(O)NH, OC(O)NH₂, S(O)₂NH, S(O)₂NH₂, NHC(O)NH₂, NHC(O)C(O)NH, NHS(O)₂NH, NHS(O)₂NH₂, C(O)NHS(O)₂, C(O)NHS(O)₂NH or C(O)NHS(O)₂NH₂, and the like, groups comprising one or more functional groups, non-aromatic hydrocarbons (optionally substituted), and groups wherein one or more carbons of a non-aromatic hydrocarbon (optionally substituted) is replaced by a functional group. Carbon atoms of an aliphatic group can be optionally oxo-substituted. An aliphatic group may be straight chained, branched, cyclic, or a combination thereof and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms. In addition to aliphatic hydrocarbon groups, as used herein, aliphatic groups expressly include, for example, alkoxyalkyls, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Aliphatic groups may be optionally substituted.

The terms “heterocyclic” or “heterocycloalkyl” can be used interchangeably and referred to a non-aromatic ring or a bi- or tri-cyclic group fused, bridged or spiro system, where (i) each ring system contains at least one heteroatom independently selected from oxygen, sulfur and nitrogen, (ii) each ring system can be saturated or unsaturated (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (v) any of the above rings may be fused to an aromatic ring, and (vi) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted or optionally substituted with exocyclic olefinic double bond. Representative heterocycloalkyl groups include, but are not limited to, 1,3-dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, 2-azabicyclo[2.2.1]-heptyl, 8-azabicyclo[3.2.1]octyl, 5-azaspiro[2.5]octyl, 1-oxa-7-azaspiro[4.4]nonanyl, 7-oxooxepan-4-yl, and tetrahydrofuryl. Such heterocyclic groups may be further substituted. Heteroaryl or heterocyclic groups can be C-attached or N-attached (where possible).

It is understood that any alkyl, alkenyl, alkynyl, alicyclic, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocyclic, aliphatic moiety or the like, described herein can also be a divalent or multivalent group when used as a linkage to connect two or more groups or substituents, which can be at the same or different atom(s). One of skill in the art can readily determine the valence of any such group from the context in which it occurs.

The term “substituted” refers to substitution by independent replacement of one, two, or three or more of the hydrogen atoms with substituents including, but not limited to, —F, —Cl, —Br, —I, —OH, C₁-C₁₂-alkyl; C₂-C₁₂-alkenyl, C₂-C₁₂-alkynyl, —C₃-C₁₂-cycloalkyl, protected hydroxy, —NO₂, —N₃, —CN, —NH₂, protected amino, oxo, thioxo, —NH—C₁-C₁₂-alkyl, —NH—C₂-C₈-alkenyl, —NH—C₂-C₈-alkynyl, —NH—C₃-C₁₂-cycloalkyl, —NH-aryl, —NH-heteroaryl, —NH— heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, —O—C₁-C₁₂-alkyl, —O—C₂-C₈-alkenyl, —O—C₂-C₈-alkynyl, —O—C₃-C₁₂-cycloalkyl, —O-aryl, —O-heteroaryl, —O— heterocycloalkyl, —C(O)—C₁-C₁₂-alkyl, —C(O)—C₂-C₈-alkenyl, —C(O)—C₂-C₈-alkynyl, —C(O)—C₃-C₁₂-cycloalkyl, —C(O)-aryl, —C(O)-heteroaryl, —C(O)-heterocycloalkyl, —CONH₂, —CONH—C₁-C₁₂-alkyl, —CONH—C₂-C₈-alkenyl, —CONH—C₂-C₈-alkynyl, —CONH—C₃-C₁₂-cycloalkyl, —CONH-aryl, —CONH-heteroaryl, —CONH-heterocycloalkyl, —OCO₂—C₁-C₁₂-alkyl, —OCO₂—C₂-C₈-alkenyl, —OCO₂—C₂-C₈-alkynyl, —OCO₂—C₃-C₁₂-cycloalkyl, —OCO₂-aryl, —OCO₂-heteroaryl, —OCO₂-heterocycloalkyl, —CO₂—C₁-C₁₂ alkyl, —CO₂—C₂-C₈ alkenyl, —CO₂—C₂-C₈ alkynyl, CO₂—C₃-C₁₂-cycloalkyl, —CO₂— aryl, CO₂-heteroaryl, CO₂-heterocyloalkyl, —OCONH₂, —OCONH—C₁-C₁₂-alkyl, —OCONH—C₂-C₈-alkenyl, —OCONH—C₂-C₈-alkynyl, —OCONH—C₃-C₁₂-cycloalkyl, —OCONH-aryl, —OCONH-heteroaryl, —OCONH-heterocyclo-alkyl, —NHC(O)H, —NHC(O)—C₁-C₁₂-alkyl, —NHC(O)—C₂—C-alkenyl, —NHC(O)—C₂-C₈-alkynyl, —NHC(O)—C₃-C₁₂-cycloalkyl, —NHC(O)-aryl, —NHC(O)-heteroaryl, —NHC(O)-heterocyclo-alkyl, —NHCO₂—C₁-C₁₂-alkyl, —NHCO₂—C₂—C-alkenyl, —NHCO₂— C₂-C₈-alkynyl, —NHCO₂—C₃-C₁₂-cycloalkyl, —NHCO₂-aryl, —NHCO₂-heteroaryl, —NHCO₂-heterocycloalkyl, —NHC(O)NH₂, —NHC(O)NH—C₁-C₁₂-alkyl, —NHC(O)NH—C₂-C₈-alkenyl, —NHC(O)NH—C₂-C₈-alkynyl, —NHC(O)NH—C₃-C₁₂-cycloalkyl, —NHC(O)NH-aryl, —NHC(O)NH-heteroaryl, —NHC(O)NH-heterocycloalkyl, NHC(S)NH₂, —NHC(S)NH—C₁-C₁₂-alkyl, —NHC(S)NH—C₂-C₈-alkenyl, —NHC(S)NH—C₂-C₈-alkynyl, —NHC(S)NH—C₃-C₁₂-cycloalkyl, —NHC(S)NH-aryl, —NHC(S)NH-heteroaryl, —NHC(S)NH-heterocycloalkyl, —NHC(NH)NH₂, —NHC(NH)NH—C₁-C₁₂-alkyl, —NHC(NH)NH—C₂—C-alkenyl, —NHC(NH)NH—C₂-C₈-alkynyl, —NHC(NH)NH—C₃-C₁₂-cycloalkyl, —NHC(NH)NH-aryl, —NHC(NH)NH-heteroaryl, —NHC(NH)NH-heterocycloalkyl, —NHC(NH)—C₁-C₁₂-alkyl, —NHC(NH)—C₂-C₈-alkenyl, —NHC(NH)—C₂-C₈-alkynyl, —NHC(NH)—C₃-C₁₂-cycloalkyl, —NHC(NH)-aryl, —NHC(NH)-heteroaryl, —NHC(NH)-heterocycloalkyl, —C(NH)NH—C₁-C₁₂-alkyl, —C(NH)NH—C₂-C₈-alkenyl, —C(NH)NH—C₂-C₈-alkynyl, —C(NH)NH—C₃-C₁₂-cycloalkyl, —C(NH)NH-aryl, —C(NH)NH-heteroaryl, —C(NH)NH-heterocycloalkyl, —S(O)—C₁-C₁₂-alkyl, —S(O)—C₂-C₈-alkenyl, —S(O)—C₂-C₈-alkynyl, —S(O)—C₃-C₁₂-cycloalkyl, —S(O)-aryl, —S(O)-heteroaryl, —S(O)-heterocycloalkyl, —SO₂NH₂, —SO₂NH—C₁-C₁₂-alkyl, —SO₂NH—C₂—C-alkenyl, —SO₂NH— C₂-C₈-alkynyl, —SO₂NH—C₃-C₁₂-cycloalkyl, —SO₂NH-aryl, —SO₂NH-heteroaryl, —SO₂NH— heterocycloalkyl, —NHSO₂—C₁-C₁₂-alkyl, —NHSO₂—C₂-C₈-alkenyl, —NHSO₂—C₂-C₈-alkynyl, —NHSO₂—C₃-C₁₂-cycloalkyl, —NHSO₂-aryl, —NHSO₂-heteroaryl, —NHSO₂-heterocycloalkyl, —CH₂NH₂, —CH₂SO₂CH₃, -aryl, -arylalkyl, -heteroaryl, -heteroarylalkyl, -heterocycloalkyl, —C₃-C₁₂-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, —SH, —S—C₁-C₁₂-alkyl, —S—C₂-C₈-alkenyl, —S—C₂-C₈-alkynyl, —S—C₃-C₁₂-cycloalkyl, —S-aryl, —S-heteroaryl, —S-heterocycloalkyl, or methylthio-methyl. It is understood that the aryls, heteroaryls, alkyls, cycloalkyls and the like can be further substituted. In certain embodiments, the substituents are independently selected from halo, preferably Cl and F; C₁-C₄-alkyl, preferably methyl and ethyl; halo-C₁-C₄-alkyl, such as fluoromethyl, difluoromethyl, and trifluoromethyl; C₂-C₄-alkenyl; halo-C₂-C₄-alkenyl; C₃-C₆-cycloalkyl, such as cyclopropyl; C₁-C₄-alkoxy, such as methoxy and ethoxy; halo-C₁-C₄-alkoxy, such as fluoromethoxy, difluoromethoxy, and trifluoromethoxy, —CN; —OH; NH₂; C₁-C₄-alkylamino; di(C₁-C₄-alkyl)amino; and NO₂. It is understood that the aryls, heteroaryls, alkyls, and the like can be further substituted. In some cases, each substituent in a substituted moiety is additionally optionally substituted with one or more groups, each group being independently selected from C₁-C₄-alkyl; —CF₃, —OCH₃, —OCF₃, —F, —Cl, —Br, —I, —OH, —NO₂, —CN, and —NH₂. Preferably, a substituted alkyl group, such as a substituted methyl group, is substituted with one or more halogen atoms, more preferably one or more fluorine or chlorine atoms.

The term “halo” or halogen” alone or as part of another substituent, as used herein, refers to a fluorine, chlorine, bromine, or iodine atom.

The term “optionally substituted”, as used herein, means that the referenced group may be substituted or unsubstituted. In one embodiment, the referenced group is optionally substituted with zero substituents, i.e., the referenced group is unsubstituted. In another embodiment, the referenced group is optionally substituted with one or more additional group(s) individually and independently selected from groups described herein.

The term “hydrogen” includes hydrogen and deuterium. In addition, the recitation of an atom includes other isotopes of that atom so long as the resulting compound is pharmaceutically acceptable.

The term “hydroxy activating group,” as used herein, refers to a labile chemical moiety which is known in the art to activate a hydroxyl group so that it will depart during synthetic procedures such as in a substitution or an elimination reaction. Examples of hydroxyl activating group include, but not limited to, mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate and the like.

The term “activated hydroxyl,” as used herein, refers to a hydroxy group activated with a hydroxyl activating group, as defined above, including mesylate, tosylate, triflate, p-nitrobenzoate, phosphonate groups, for example.

The term “hydroxy protecting group,” as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed. Hydroxy protecting groups as known in the art are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl protecting groups include benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, tert-butoxy-carbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, allyl, benzyl, triphenyl-methyl (trityl), methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-(trimethylsilyl)-ethoxymethyl, methanesulfonyl, trimethylsilyl, triisopropylsilyl, and the like.

The term “protected hydroxy,” as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.

The term “hydroxy prodrug group,” as used herein, refers to a promoiety group which is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group in vivo. Hydroxy prodrug groups as known in the art are described generally in Kenneth B. Sloan, Prodrugs, Topical and Ocular Drug Delivery, (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).

The term “amino protecting group,” as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed. Amino protecting groups as known in the art are described generally in T. H. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, methoxycarbonyl, t-butoxycarbonyl, 9-fluorenyl-methoxycarbonyl, benzyloxycarbonyl, and the like.

The term “protected amino,” as used herein, refers to an amino group protected with an amino protecting group as defined above.

The term “leaving group” means a functional group or atom which can be displaced by another functional group or atom in a substitution reaction, such as a nucleophilic substitution reaction. By way of example, representative leaving groups include chloro, bromo and iodo groups; sulfonic ester groups, such as mesylate, tosylate, brosylate, nosylate and the like; and acyloxy groups, such as acetoxy, trifluoroacetoxy and the like.

The term “aprotic solvent,” as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor. Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, N Y, 1986.

The term “protic solvent,” as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, and the like. Such solvents are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of Chemistry Series, John Wiley & Sons, N Y, 1986.

Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable,” as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).

The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the Formula herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, 2^(nd) Ed. Wiley-VCH (1999); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), and subsequent editions thereof.

The term “subject,” as used herein, refers to an animal. Preferably, the animal is a mammal. More preferably, the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.

The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.

The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or as (D)- or (L)-for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981). When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans-isomers. Likewise, all tautomeric forms are also intended to be included. Tautomers may be in cyclic or acyclic. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.

Certain compounds of the present invention may also exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of these compounds and mixtures thereof.

As used herein, the term “pharmaceutically acceptable salt,” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.

As used herein, the term “pharmaceutically acceptable ester” refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.

PHARMACEUTICAL COMPOSITIONS

The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.

As used herein, the term “pharmaceutically acceptable carrier or excipient” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.

The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectable.

The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.

Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.

The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

For pulmonary delivery, a therapeutic composition of the invention is formulated and administered to the patient in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to Van Devanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98/43650 by Montgomery, all of which are incorporated herein by reference).

Antiviral Activity

An inhibitory amount or dose of the compounds of the present invention may range from about 0.01 mg/Kg to about 500 mg/Kg, alternatively from about 1 to about 50 mg/Kg. Inhibitory amounts or doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents.

According to the methods of treatment of the present invention, viral infections, conditions are treated or prevented in a patient such as a human or another animal by administering to the patient a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result.

By a “therapeutically effective amount” of a compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and like factors well known in the medical arts.

The total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a patient in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.

The compounds of the present invention described herein can, for example, be administered by injection, intravenously, intra-arterial, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations may contain from about 20% to about 80% active compound.

Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

When the compositions of this invention comprise a combination of a compound of the Formula described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

The said “additional therapeutic or prophylactic agents” includes but not limited to, immune therapies (eg. interferon), therapeutic vaccines, antifibrotic agents, anti-inflammatory agents such as corticosteroids or NSAIDs, bronchodilators such as beta-2 adrenergic agonists and xanthines (e.g. theophylline), mucolytic agents, anti-muscarinics, anti-leukotrienes, inhibitors of cell adhesion (e.g. ICAM antagonists), anti-oxidants (eg N-acetylcysteine), cytokine agonists, cytokine antagonists, lung surfactants and/or antimicrobial and anti-viral agents (e.g. ribavirin and amantidine). The compositions according to the invention may also be used in combination with gene replacement therapy.

Combination and Alternation Therapy

It has been recognized that drug-resistant variants of HIV, HBV and HCV can emerge after prolonged treatment with an antiviral agent. Drug resistance most typically occurs by mutation of a gene that encodes for a protein such as an enzyme used in viral replication, and most typically in the case of HIV, reverse transcriptase, protease, or DNA polymerase, and in the case of HBV, DNA polymerase, or in the case of HCV, RNA polymerase, protease, or helicase. Recently, it has been demonstrated that the efficacy of a drug against HIV infection can be prolonged, augmented, or restored by administering the compound in combination or alternation with a second, and perhaps third, antiviral compound that induces a different mutation from that caused by the principle drug. The compounds can be used for combination are selected from the group consisting of a HBV polymerase inhibitor, interferon, TLR modulators such as TLR-7 agonists or TLR-8 agonists, therapeutic vaccines, immune activator of certain cellular viral RNA sensors, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, antiviral compounds of distinct or unknown mechanism, and combination thereof. Alternatively, the pharmacokinetics, biodistribution, or other parameter of the drug can be altered by such combination or alternation therapy. In general, combination therapy is typically preferred over alternation therapy because it induces multiple simultaneous stresses on the virus.

Preferred compounds for combination or alternation therapy for the treatment of HBV include 3TC, FTC, L-FMAU, interferon, siRNA, adefovir dipivoxil, entecavir, telbivudine (L-dT), valtorcitabine (3′-valinyl L-dC), β-D-dioxolanyl-guanine (DXG), β-D-dioxolanyl-2,6-diaminopurine (DAPD), and β-D-dioxolanyl-6-chloropurine (ACP), famciclovir, penciclovir, lobucavir, ganciclovir, and ribavirin.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

ABBREVIATIONS

Abbreviations which may be used in the descriptions of the scheme and the examples that follow are: Ac for acetyl; AcOH for acetic acid; AIBN for azobisisobutyronitrile; BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; Boc₂O for di-tert-butyl-dicarbonate; Boc for t-butoxycarbonyl; Bpoc for 1-methyl-1-(4-biphenylyl)ethyl carbonyl; Bz for benzoyl; Bn for benzyl; BocNHOH for tert-butyl N-hydroxycarbamate; t-BuOK for potassium tert-butoxide; Bu₃SnH for tributyltin hydride; BOP for (benzotriazol-1-yloxy)tris(dimethylamino)phospho-nium Hexafluorophosphate; Brine for sodium chloride solution in water; BSA for N,O-bis(trimethylsilyl)acetamide; CDI for carbonyldiimidazole; DCM or CH₂C₁₂ for dichloro-methane; CH₃ for methyl; CH₃CN for acetonitrile; Cs₂CO₃ for cesium carbonate; CuCl for copper (I) chloride; CuI for copper (I) iodide; dba for dibenzylidene acetone; dppb for diphenylphos-phinobutane; DBU for 1,8-diazabicyclo[5.4.0]-undec-7-ene; DCC for N,N′-dicyclohexyl-carbodiimide; DEAD for diethylazodicarboxylate; DIAD for diisopropyl azodicarboxylate; DIPEA or (i-Pr)₂EtN for N,N,-diisopropylethyl amine; Dess-Martin periodinane for 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3-(1H)-one; DMAP for 4-dimethylamino-pyridine; DME for 1,2-dimethoxyethane; DMF for N,N-dimethylformamide; DMSO for dimethyl sulfoxide; DMT for di(p-methoxyphenyl)-phenylmethyl or dimethoxy-trityl; DPPA for diphenylphosphoryl azide; EDC for N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide; EDC HCl for N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride; EtOAc for ethyl acetate; EtOH for ethanol; Et₂O for diethyl ether; HATU for O-(7-azabenzotriazol-1-yl)-N,N,N′,N′,-tetramethyluronium Hexafluoro-phosphate; HCl for hydrogen chloride; HOBT for 1-hydroxybenzotriazole; K₂CO₃ for potassium carbonate; n-BuLi for n-butyl lithium; i-BuLi for i-butyl lithium; t-BuLi for t-butyl lithium; PhLi for phenyl lithium; LDA for lithium diisopropylamide; LiTMP for lithium 2,2,6,6-tetramethyl-piperidinate; MeOH for methanol; Mg for magnesium; MOM for methoxymethyl; Ms for mesyl or —SO₂—CH₃; Ms₂O for methanesulfonic anhydride or mesyl-anhydride; MTBE for t-butyl methyl ether; NaN(TMS)₂ for sodium bis(trimethylsilyl)amide; NaCl for sodium chloride; NaH for sodium hydride; NaHCO₃ for sodium bicarbonate or sodium hydrogen carbonate; Na₂CO₃ sodium carbonate; NaOH for sodium hydroxide; Na₂SO₄ for sodium sulfate; NaHSO₃ for sodium bisulfite or sodium hydrogen sulfite; Na₂S₂O₃ for sodium thiosulfate; NH₂NH₂ for hydrazine; NH₄HCO₃ for ammonium bicarbonate; NH₄Cl for ammonium chloride; NMO for N-methylmorpholine N-oxide; NaIO₄ for sodium periodate; Ni for nickel; OH for hydroxyl; OsO₄ for osmium tetroxide; PPA for polyphophoric acid; PTSA for p-toluenesulfonic acid; PPTS for pyridiniump-toluenesulfonate; PhI(OPiv)₂ for Bis(tert-butylcarbonyloxy)iodobenzene; Rh₂(Esp)₂ for Bis[rhodium(α,α,α′,α′-tetramethyl-1,3-benzenedipropionic acid)]; TBAF for tetrabutylammonium fluoride; TEA or Et₃N for triethylamine; TES for triethylsilyl; TESCl for triethylsilyl chloride; TESOTf for triethylsilyl trifluoromethanesulfonate; TFA for trifluoroacetic acid; THF for tetrahydrofuran; TMEDA for N,N,N′,N′-tetramethylethylene-diamine; TPP or PPh₃ for triphenyl-phosphine; Troc for 2,2,2-trichloroethyl carbonyl; Ts for tosyl or —SO₂—C₆H₄CH₃; Ts₂O for tolylsulfonic anhydride or tosyl-anhydride; TsOH for p-tolylsulfonic acid; Pd for palladium; Ph for phenyl; POPd for dihydrogen dichlorobis(di-tert-butylphosphinito-κP)palladate(II); Pd₂(dba)₃ for tris(diben-zylideneacetone) dipalladium (0); Pd(PPh₃)₄ for tetrakis(triphenylphosphine)-palladium (0); PdCl₂(PPh₃)₂ for trans-dichlorobis-(triphenylphosphine)palladium (II); Pt for platinum; Rh for rhodium; rt for room temperature; Ru for ruthenium; TBS for tert-butyl dimethylsilyl; TMS for trimethylsilyl; or TMSCl for trimethylsilyl chloride.

Synthetic Methods

The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared. These schemes are of illustrative purpose, and are not meant to limit the scope of the invention. Equivalent, similar, or suitable solvents, reagents or reaction conditions may be substituted for those particular solvents, reagents, or reaction conditions described herein without departing from the general scope of the method of synthesis.

The nature of the group B in Formula I will have a significant effect on the choice of the synthesis methods, as demonstrated below:

When B in Formula I is a hydrogen, an illustrative method is shown in Schemes 1, the X, A, Y, Z are as defined as previously for formula I. The starting material aldehyde I-1, a ketone I-2 wherein Y is an electron withdrawing group, such as an ester, or an aromatic group (the desired aryl or heteroaryl) and an amidine 1-3 are all either commercially available or can be easily prepared by those familiar with the skill of the arts. The dihydropyrimidine core I-4 can be prepared in one pot process from an aldehyde I-1, a ketone I-2 and an amidine I-3 (or its salt) in the presence of a suitable base as such potassium acetate or potassium bicarbonate in a solvent like methanol, or trifluoroethanol. Most frequently, elevated temperature is required for this transformation. Starting from this core 1-4, A, X, Y, Z could be individually manipulated and converted to varieties of functional groups.

For instance, when Z in I-4 is a methyl, this methyl can be further functionalized easily. One specific example is shown in scheme 1a, when I-4a is treated with NBS, the methyl bromide I-5 will be obtained. The bromide can be displaced with nucleophiles. Therefore, when I-5a is reacted with various bi-functional molecules Z′(CH₂)_(m)GH, in which GH is a nucleophile, such as an amine, an alcohol or a malonate; Z′ is precursor of a leaving group, such as a protected hydroxyl or a ester, in the presence of a suitable base such as TEA or pyridine, will provide a more complicated structure I-6a. Next the Z′ is converted to a desired leaving group by either de-protection or reduction to free the alcohol, followed by mesylate formation to afford the 1-7a. Alternatively, bromide or tosylate may be used. When 1-7a is treated with a base, like TEA or K₂CO₃, in a proper solvent such as THF, acetonitrile or DMF will give the cyclized product 1-8a.

Next, Y in the formula I-8a can be further manipulated. For instance, as shown in Scheme 1b, wherein Y is an ester, R₃ is as defined as previously. In the case while R₃ is t-Butyl or allyl, then ester I-8b can be converted to an advanced carboxyl acid intermediate I-9b when treated with strong acid (HCl or TFA) or Pd(PPh₃)₄/Morpholine, respectively. By taking advantage of this carboxyl acid as a key intermediate, various functional groups can be generated from it. One specific example is shown in the same scheme, this carboxyl acid is converted to the acyl chloride followed by treating with amines to give the amide I-10b. Alternatively this transformation also can be completed in the presence of a dehydration reagent such as EDC or DCC as well as a base like TEA, DIPEA. When R₁ and R₂ are hydrogen, this amide when treated with a dehydration reagent such as TFAA will afford a nitrile. This nitrile can serve as advanced intermediate for azoles. When R₁ is methyl, R₂ is methoxyl, a Weinreb amide is obtained. In the next step, this Weinreb amide is reduced to an aldehyde or reacted with all sorts of Grignard reagent will offer various ketone, which could serve as later stage intermediate for further functional group manipulation for more complicated heteroaryl including azoles. One example is shown in the same scheme, the Weinreb amide I-10b can be reduced to afford the aldehyde I-11b, which when reacted with acetone in the presence of a base such as LDA will offer the α,β-unsaturated ketone 1-12b. I-12b is treated with hydroxyl amine followed by an iodine induced cyclization to afford the isoxazole I-13c. More related arts can be found in the various publications (for example, J. A Joule and K. Mills, Heterocyclic Chemistry, 5^(th) edition, 557 and reference therein). G, m′ and R₃ are as previously defined.

In yet another specific example as shown in Scheme 1c, when the carboxyl acid I-9b is treated with pyridinium tribromide in the presence a base such as pyridine, a bromide I-10c will be produced. The bromide reacts with various aryl or heteroaryl boronic ester/acid or tin reagent, which can be commercial available or easily prepared by those familiar with the skill of the arts, under the Pd(0) catalyzed coupling conditions to give the target molecule I-11c. (see reviews: A. Suzuki, Pure Applied Chem., 1991, 63, 419; A. Suzuki, Handbook of Organopalladium Chemistry for Organic Synthesis, 2002, 1, 249; A. Anastasia, et al, Handbook of Organopalladium Chemistry for Organic Synthesis, 2002, 1, 311).

In yet another specific example as shown Scheme 1d, the compound I-4d can be protected with a proper protecting group such as Boc, or Cbz to give I-5d. Hydrolysis the ester of I-5d following similar procedure as described in Scheme 1b will afford the acid I-6d. When the carboxyl acid I-6d is treated with at least two equivalents of NBS, the di-bromo compound I-7d will be obtained. Starting from this di-bromo I-7d, following similar chemical procedure described in Scheme 1a for converting I-5a to I-8a, the 5-bromo compound I-10c will be generated. From it, target I-11c will be obtained as discussed in Scheme 1c.

In yet another specific example as shown Scheme 1e, if the amidine I-3 shown in Scheme 1 is replaced with a urea, a dihydropyrimidine-2-one I-4a analogue to I-4 is generated. It is well known in literature (A. Karnail, et al, Journal of Organic Chemistry, 1989, 54, 5898) that when this family molecules are treated with (Boc)₂O in the present of a base such as TEA, or DIPEA, a N-3 Boc protected product I-5e will be obtained. Alkylation of this intermediate I-5e with an alkylation reagent, like RBr with the desired R group in the presence of a proper base such as NaH will afford the N-1 alkylated intermediate I-6e. When I-6e is treated with an acid, like HCl or TFA, the N-3 Boc protecting group will be removed, which is followed by heating this material in POCl₃ to lead to the 2-chloro dihydropyrimidine I-7e. This chloride reacts with various aryl or heteroaryl boronic ester/acid or tin reagent, which can be commercial available or easily prepared by those familiar with the skill of the arts, under the Pd(0) catalyzed coupling conditions to give the target molecule I-8e contains the desired A group. When I-8e is reacted with 1 equivalent NBS, the 6-methyl will be brominated to offer advanced intermediated I-9e. The bromide in I-9e can be displaced with the desired M group with MH in the presence of proper base to afford I-10e. In molecule I-10e, if the Y is desired aryl or heteroaryl group, then I-10e is a desired target; if Y is an ester, then all the chemistry described in Scheme 1b and Scheme 1c can be applied to afford the desired product. R and M are as previously defined.

On the other hand, if the R in I-9e contains a nucleophile such as I-9e′ as shown in Scheme if, when treated with a base, TEA, or NaH will afford the intermediate I-8a.

In yet another specific example as shown in Scheme 1g, the ketone I-2g can be commercially available or easily prepared by those familiar with the skill of the arts, wherein Z is a methyl group with a bi-functional group Z′(CH₂)_(m)G attached, in which G-H is a nucleophile, such as an amine, an alcohol or a malonate; The one-pot ring formation process involving a aldehyde I-1, a ketone I-2g and an amidine I-3 (or its salt) similar as described in Scheme 1 will provide a more complicated dihydropyrimidine I-6a. Z′ is precursor of a leaving group, such as a protected hydroxyl or a ester. Following a similar reaction sequence as in Scheme 1a, dihydropyrimidine I-6a can be converted to cyclized product I-8a. In the case where Y is a t-butyl or allyl ester or other activated ester, Y can be transformed into an aryl group following the reaction sequence as describe in Scheme 1b and Scheme 1c. Alternatively, Y in dihydropyrimidine I-6a can be converted to an ary group first, followed by transformation of Z′ and the ensuing cyclization to afford I-11c.

On the other hand when B is CN or an alkyl group, a step wise route is required for the preparation of the final targets. As illustrated in Scheme 2, aldehyde I-1 and I-2 are reacted with each other in the presence of a catalyst system, such as piperidine/acetic acid to afford the α,β-unsaturated ketone II-1. This α,β-unsaturated ketone II-1 reacts with a copper reagent CuB, which can be commercially available or can be easily generated in situ from CuI and BMgX (or BLi). The newly formed α,β-unsaturated ketone II-2 then reacts with I-3 in a similar process described above as in the one-pot process to afford the desired target I.

In a specific example, while B is a methyl, X is a aryl or heteroaryl, I in Scheme 2 can be introduced with a chemistry described in Scheme 2a following similar published precedents (For example, WO 2013/102655). A distal acetylene I-1a served as a methyl ketone equivalent reacts with ketone I-2 in the presence of InCl₃ will provide the α,β-unsaturated ketone II-1a, which in turn when reacts with amidine I-3 will provide Ia, the 4-methyl analogue of I.

With I in hand, all the chemistry described in Scheme 1a to Scheme if can be applied here to give the desired targets.

Alternatively, in certain cases, even when B is hydrogen, a step wise procedure similar as in Scheme 2 is required to achieve the targets.

It will be appreciated that, with appropriate manipulation and protection of any chemical functionality, synthesis of compounds of Formula (I) is accomplished by methods analogous to those above and to those described in the Experimental section. Suitable protecting groups can be found, but are not restricted to, those found in T W Greene and P G M Wuts “Protective Groups in Organic Synthesis”, 3rd Ed (1999), J Wiley and Sons.

All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.

Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.

Although the invention has been described with respect to various preferred embodiments, it is not intended to be limited thereto, but rather those skilled in the art will recognize that variations and modifications may be made therein which are within the spirit of the invention and the scope of the appended claims.

EXAMPLES

The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention.

Step 1-1a.

A solution of ethyl (R)-2-hydroxypropanoate (5 g, 42.3 mmol) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (6 g, 42.3 mmol) was stirred for 4 hours at 120° C. The mixture was concentrated under vacuum to give desired product (9 g, crude) as yellow oil, which was used in the next step without further purification. ESI MS m/z=203.25 [M+H]⁺.

Step 1-1b.

A solution of the compound from step 1-1a (5 g, 24.5 mmol), 2-chloro-4-fluorobenzaldehyde (4.3 g, 27.3 mmol), TsOH (cat) and HOAc (cat) in toluene (60 mL) was stirred at 110° C. overnight. The mixture was concentrated. The residue was chromatographed (silica, ethyl acetate/petroleum ether) to give the desired product (5.93g, 70.0%) as yellow solid. ESI MS m/z=343.00 [M+H]⁺.

Step 1-1c.

A solution of the compound from step 1-1b (5 g, 14.6 mmol), thiazole-2-carboximidamide HCl salt (2.38 g, 14.6 mmol) and K₂CO₃ (2.01 g, 14.6 mmol) in DMF (20 mL) was stirred for 2 hours at 80° C. It was diluted with EtOAc and washed with brine, filtered and concentrated. After the residue was purified by silica gel column (ethyl acetate/petroleum ether), the mixture was recrystallized from EtOH at 0° C. to give the desired product as yellow solid (1.25 g, 25.0%). ESI MS m/z=452.05 [M+H]⁺.

Step 1-1d.

A solution of the compound from step 1-1c (950 mg, 2.10 mmol), (Boc)₂O (915.6 mg, 4.20 mmol) and DMAP (307 mg, 2.51 mmol) in DCM (30 mL) was stirred for 1 hour at rt. The reaction mixture was concentrated. The residue was chromatographed (silica, ethyl acetate/petroleum ether) to give the desired compound as a yellow solid (1.07 g, 92%). ESI MS m/z=552.30 [M+H]⁺.

Step 1-1e.

A solution of the compound from step 1-1d (965 mg, 1.75 mmol) in a solution of NaOH [40 mL, 2M in H₂O/MeOH (1:5)] was stirred for 18 hours at rt. After being acidified with aq HCl (4N) to pH 5, the mixture was extracted with DCM. The organic layer was washed with aq. NH₄Cl and H₂O, dried (Na₂SO₄) and concentrated. The residue was chromatographed (silica, ethyl acetate/petroleum ether) to give the desired compound as yellow solid (620 mg, 78%). ESI MS m/z=452.15 [M+H]⁺.

Step 1-1f.

A solution of the compound from step 1-1e (250 mg, 0.55 mmol) in DCM (10 mL) was treated with NBS (295 mg, 1.66 mmol) for 6 hours at rt. The reaction was quenched by the addition of water (2 mL) and extracted with DCM. The organic layer was dried (Na₂SO₄), concentrated. The residue was chromatographed (C₁₈ column, MeCN/H₂O) to give the title compound as yellow solid (103.5 mg, 33%). ESI MS m/z=566.10, 568.10 [M+H]⁺. ¹H NMR (400 MHz, DMSO-d6) δ 8.04 (m, 2H), 7.98 (d, 1H), 7.57 (m, 1H), 7.23 (m, 1H), 6.35 (s, 1H), 4.45 (m, 2H), 1.15 (s, 9H).

Step 1a.

To a suspension of Intermediate 1 (15.00 g, 25.60 mmol) and ethyl 2-((diphenylmethylene)amino)acetate (14.18 g, 53.0 mmol) in toluene (270 ml) cooled at 0° C. was added O-Allyl-N-(9-anthracenylmethyl)cinchonidinium bromide (1.606 g, 2.650 mmol), followed by 50% KOH aq (88.0 ml, 1.326 mol) dropwise. The mixture was vigorously stirred at 0° C. for 2 h before being diluted with saturated NaHCO₃ aq and MTBE. The organic layer was washed with saturated NaHCO₃ aq (*1), brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the desired compound as red oil, which was used directly for next step. ESI MS m/z=751.14, 753.14 [M+H]⁺.

Step 1b.

A clear orange solution of the compound from step 1a (25.60 mmol) in THF (100 ml), Water (100.00 ml) and AcOH (66.67 ml) was stirred at rt for 4 h before being concentrated. The residue was carefully diluted with DCM and saturated NaHCO₃ aq. The organic layer was dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the desired compound as a red oil, which was used directly for next step. ESI MS m/z=587.06, 589.06 [M+H]⁺.

Step 1c.

To a clear yellow solution of the compound from step 1b (25.60 mmol) in DCM (200 ml) at rt was added DMAP (6.260 g, 51.2 mmol), followed by cyclopropanesulfonyl chloride (3.13 ml, 30.7 mmol) dropwise. The solution was stirred at rt for 2.5 h before excess i-PrOH was added at rt. After 5 min, the mixture was partitioned between DCM and water. The organic layer was dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc). The fractions containing the desired product were concentrated. The residue was recrystallized from DCM/heptane to afford the desired compound as yellow solid (10.73 g, 61% over 3 steps). ESI MS m/z=691.06, 693.06 [M+H]⁺. ¹H NMR showed the diastereomeric ratio was >15/1.

Step 1d.

To a solution of the compound from step 1c (3.607 g, 5.21 mmol) in THF (50 ml) at 0° C. was added LiBH₄ (2.0 M in THF, 9.12 ml, 18.24 mmol). The mixture was stirred at 0° C. for 0.5 h and then at rt for 2.5 h. EtOAc (8 ml) was added dropwise at rt to quench the reaction. After 20 min at rt, the mixture was poured portionwise into a mixture of 10% citric acid solution and EtOAc. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the desired compound as yellow foam (2.460 g, 73%). ESI MS m/z=649.05, 651.05 [M+H]⁺.

Step 1e.

To a solution of the compound from step 1d (0.600 g, 0.923 mmol) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.338 g, 1.385 mmol) in DME (10 ml) and Water (3.33 ml) at rt was added sodium bicarbonate (0.310 g, 3.69 mmol), followed by Pd(Ph₃P)₄ (0.160 g, 0.138 mmol). The mixture was flushed with N₂ before being heated at 140° C. using a microwave reactor for 30 min. The mixture was allowed to cool down and diluted with DCM and water. The aqueous layer was extracted with DCM (*1). The combined organic layeres were dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc/MeOH) to afford the desired compound as yellow foam (0.355 g, 65%). ESI MS m/z=587.10, 589.09 [M+H]⁺.

Step 1f.

To a solution of the compound from step 1e (0.120 g, 0.205 mmol) in DCM (3 ml) at 0° C. was added DMAP (75 mg, 0.615 mmol), followed by a solution of methanesulfonyl chloride (0.032 ml, 0.410 mmol) in DCM (0.1 ml). The solution was stirred at 0° C. for 0.5 h and then heated at 35° C. for 4 h. The mixture was allowed to cool down to rt diluted with DCM and 0.1 N HCl aq. The aqueous layer was extracted with DCM (*1). The combined organic layeres were washed with saturated NaHCO₃ aq, dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the desired compound as yellow solid (0.075 g, 64%). ESI MS m/z=569.08, 571.08 [M+H]⁺.

Step 2a.

To a solution of the compound from step 1b (26.0 g, 44.2 mmol) in THF (200 ml) at rt was added a solution of Boc-anhydride (11.29 ml, 48.6 mmol) in THF (15 ml) slowly. The resulting solution was stirred at rt for 2 h before being concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the desired compound as yellow solid (30.00 g, 99%). ESI MS m/z=687.12, 689.12 [M+H]⁺.

Step 2b.

To a solution of the compound from step 2a (17.50 g, 25.4 mmol) in THF (170 ml) at rt was added LiBH₄ (2.0 M in THF, 38.2 ml, 76 mmol) dropwise. The mixture was stirred at rt for 3 h. HOAc (9 ml) was added dropwise until no bubble was observed. The mixture was diluted with EtOAc and saturated NH₄Cl aq. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the desired compound as yellow foam (6.152 g, 37%). ESI MS m/z=645.11, 647.11 [M+H]⁺.

Step 2c.

To a solution of the compound from step 2b (2.750 g, 4.26 mmol) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.558 g, 6.39 mmol) in Dioxane (36 ml) and Water (12.00 ml) at rt was added sodium bicarbonate (1.431 g, 17.03 mmol), followed by Pd(Ph₃P)₄ (0.738 g, 0.639 mmol). The mixture was flushed with N₂ before being heated at 110° C. in a sealed thick-wall flask for 22 h. The mixture was allowed to cool down and diluted with DCM and water. The aqueous layer was extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the desired compound as yellow foam (1.565 g, 63%). ESI MS m/z=583.15, 585.15 [M+H]⁺.

Step 2d.

To a solution of the compound from step 2c (1.565 g, 2.68 mmol) in DCM (50 ml) at 0° C. was added DMAP (0.984 g, 8.05 mmol), followed by methanesulfonyl chloride (0.418 ml, 5.37 mmol) dropwise. The solution was stirred at 0° C. for 0.5 h and then heated at 35° C. for 4 h before being allowed to cool down to rt and concentrated. The residue was taken up in DCM and filtered. The filtrate was directly purified by flash column chromatography (silica, hexanes/EtOAc) to afford the title compound as yellow foam (0.840 g, 55%). ESI MS m/z=563.15, 565.14 [M+H]⁺.

Step 1g.

To a solution of Example 2 (0.840 g, 1.487 mmol) in DCM (15 ml) at rt was added 4 M HCl in 1,4-dioxane (7.43 ml, 29.7 mmol). The suspension was stirred at rt for 1 h before being poured into a mixture of DCM and saturated NaHCO₃ aq. The solid was rinsed into the separatory funnel with DCM and some Et₃N. The two layers were separated. The aqueous layer was extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by flash column chromatography (silica, DCM/MeOH/Et₃N) to afford the desired compound as yellow foam (0.583 g, 84%) as a single diastereomer. ESI MS m/z=465.08, 467.08 [M+H]⁺.

Step 1h.

To a yellow solution of the compound from step 1g (0.270 g, 0.581 mmol) in DCM (9 ml) at rt was added DMAP (0.142 g, 1.162 mmol), followed by cyclopropanesulfonyl chloride (0.089 ml, 0.871 mmol). The solution was stirred at rt for 1 h before being quenched with excess i-PrOH at rt. The mixture was concentrated. The residue was purified by flash column chromatography (silica, hexanes/EtOAc) to afford the title compound as yellow foam (0.290 g, 88%). ESI MS m/z=569.08, 571.08 [M+H]⁺.

Step 3a.

To a solution of the compound from step 1d (1.470 g, 2.67 mmol) and DIPEA (1.868 ml, 10.69 mmol) in DCE (30 ml) at rt was added methanesulfonic anhydride (0.699 g, 4.01 mmol) in one portion. The resulting clear yellow solution was stirred at rt for 0.5 h and then at 55° C. for 2 h before being allowed to cool down and quenched with excess i-PrOH. After 10 min at rt, the mixture was concentrated. The residue was directly purified by flash column chromatography (silica, hexanes/EtOAc) to afford the title compound as yellow foam (0.630 g, 44%). ESI MS m/z=530.97, 532.97 [M+H]⁺.

Step 3b.

To a solution of 3-bromo-1-cyclopropyl-1H-pyrazole (0.400 g, 2.139 mmol) in toluene (10 ml) at rt was added bis(tributyltin) (1.618 ml, 3.21 mmol), followed by Pd(Ph₃P)₄ (0.247 g, 0.214 mmol). The solution was stirred at 150° C. using a microwave reactor for 45 min. The dark mixture was directly purified by flash column chromatography (silica, hexanes/MTBE) to afford the desired compound as colorless liquid (0.240 g, 28%). ESI MS m/z=397.16, 399.16 [M+H]⁺.

Step 3c.

To a solution of the compound from step 3a (50.0 mg, 0.094 mmol) and the compound from step 3b (74.7 mg, 0.188 mmol) in toluene (2 ml) at rt was added Pd(Ph₃P)₄ (16.30 mg, 0.014 mmol). The mixture was flushed with N₂ before being heated at 140° C. using a microwave reactor for 30 min. The mixture was directly purified by flash column chromatography (silica, hexanes/MTBE). The fractions containing the desired product were combined and concentrated. The solid residue was purified by HPLC (CH₃CN/water) to afford the title compound as yellow solid (8.0 mg, 15%). ESI MS m/z=559.11, 561.11 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 1. ESI MS m/z=519.08, 521.08 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 1. ESI MS m/z=561.13, 563.13 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 1. ESI MS m/z=559.12, 561.11 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 1. ESI MS m/z=601.09, 603.09 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 1. ESI MS m/z=587.08, 589.07 [M+H]⁺.

A solution of the compound from step 1g (50.0 mg, 0.108 mmol) and sulfamide (41.3 mg, 0.430 mmol) in 1,4-dioxane (2 ml) was flushed with N₂ and then heated at 110° C. in a sealed microwave tube for 6 h. The mixture was allowed to cool down and freed of volatile with a stream of N₂. The residue was taken up in DCM and directly purified by flash column chromatography (silica, DCM/MeOH) to afford the title compound as yellow solid (33.5 mg, 57%). ESI MS m/z=544.06, 546.06 [M+H]⁺.

To a solution of the compound from step 1g (30.0 mg, 0.065 mmol) in DCM (2 ml) at 0° C. was added triethylamine (0.027 ml, 0.194 mmol), followed by methanesulfonyl chloride (7.54 μl, 0.097 mmol). The mixture was stirred at 0° C. for 30 min and then at rt for 1 h. The mixture was freed of volatile with a stream of N₂. The residue was directly purified by flash column chromatography (silica, DCM/MeOH) to afford the title compound as yellow solid (32.0 mg, 91%). ESI MS m/z=543.06, 545.06 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=558.08, 560.07 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=584.10, 586.09 [M+H]⁺.

To a solution of the compound from step 1g (20.0 mg, 0.043 mmol) in DCM (1 ml) at 0° C. was added triethylamine (0.030 ml, 0.215 mmol), followed by a solution of dimethylsulfamoyl chloride (9.27 mg, 0.065 mmol) in DCM (0.1 ml). The mixture was stirred at 0° C. for 1 h. Catalytic amount of DMAP was added. The mixture was stirred at 0° C. for 0.5 h. More dimethylsulfamoyl chloride (9.27 mg, 0.065 mmol) and triethylamine (0.030 ml, 0.215 mmol) were added. The mixture was stirred at rt for 2 days before being quenched with excess i-PrOH. The mixture was freed of volatile with a stream of N₂. The residue was directly purified by flash column chromatography (silica, Hexanes/EtOAc) to afford the title compound as yellow solid (13.2 mg, 54%). ESI MS m/z=572.09, 574.09 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=523.09, 525.09 [M+H]⁺.

Step 15a.

To a suspension of methanesulfonamide (0.500 g, 5.26 mmol) and triethylamine (2.198 ml, 15.77 mmol) in DCM (16 ml) cooled at 0° C. was added phenyl chloroformate (0.659 ml, 5.26 mmol) dropwise. The resulting milky suspension was stirred at 0° C. for 1 h and then at rt for 1 h. It was filtered through a short pad of celite. The filtrate was concentrated. The residue was taken up in ether/DCM (1/1, 10 ml) and filtered through a short pad of celite. The filtrate was concentrated. The residue was dried under vacuum to afford the desired compound as colorless oil (1.570 g, 94%) as its triethylamine salt. ¹H NMR (400 MHz, Chloroform-d) δ 7.38-7.31 (m, 2H), 7.20-7.08 (m, 3H), 3.17 (q, J=7.3 Hz, 6H), 3.11 (s, 3H), 1.34 (t, J=7.3 Hz, 9H).

Step 15b.

A clear solution of the compound from step 1g (20.0 mg, 0.043 mmol) and the compound from step 15a (14.97 mg, 0.047 mmol) in THF (1 ml) was stirred at rt for 2.5 h. The mixture was freed of volatile with a stream of N₂. The residue was directly purified by flash column chromatography (silica, Hexanes/EtOAc) to afford the title compound as yellow solid (11.0 mg, 44%). ESI MS m/z=586.08, 588.07 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 15. ESI MS m/z=612.09, 614.09 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 15. ESI MS m/z 10=648.10, 650.10 [M+H]63 OF 149.

To a clear solution of the compound from step 1g (20.0 mg, 0.043 mmol) and DIPEA (0.023 ml, 0.129 mmol) in THE (1 ml) was added dimethylcarbamic chloride (3.96 μl, 0.043 mmol) at rt. The resulting solution was stirred at rt for 4 h before being quenched with excess i-PrOH. After 5 min at rt, the mixture was freed of volatile with a stream of N₂. The residue was purified by HPLC (water/CH₃CN) to afford the title compound as yellow solid (15.0 mg, 65%). ESI MS m/z=536.12, 538.12 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 13. ESI MS m/z=598.11, 600.11 [M+H]⁺.

To a solution of acetic acid (1.579 μl, 0.028 mmol) in DCM (1 ml) at rt was added EDC (7.05 mg, 0.037 mmol), followed by DMAP (4.49 mg, 0.037 mmol). After 5 min at rt, the solution was added into a vial containing Example 9 (10 mg, 0.018 mmol). The resulting solution was stirred at rt overnight before being freed of volatile with a stream of N₂. The residue was directly purified by HPLC (CH₃CN/water) to afford the desired product as its DMAP salt. The fraction containing the desired product were combined and concentrated. The residue was dissolved in DCM (5 ml) and washed with 10% citric acid aq (*2). The organic layer was dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the title compound as yellow solid (3.0 mg, 27%). ESI MS m/z=586.07, 588.07 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=557.08, 559.08 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=571.10, 573.10 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=585.12, 587.11 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=571.10, 573.10 [M+H]⁺.

Step 25a.

To a solution of (R)-4-benzyl-3-(2-(benzyloxy)acetyl)oxazolidin-2-one (108 mg, 0333 mmol) in THF (2 mL) at −78° C. was added LHMDS (0.4 mL, 0.400 mmol, 1 M in THF). The reaction mixture was stirred for 20 minutes at −78° C. A solution of Intermediate 1 (282 mg, 0.500 mmol) in THF (1 mL) was added. The reaction mixture was allowed to warm up to rt and stirred at rt for 1 h. The reaction mixture was quenched with saturated NH₄Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the desired compound as yellow foam (120 mg, 81%). ESI-MS m/z=809.16, 811.15 [M+H]⁺.

Step 25b.

To a solution of the compound from step 25a (180 mg, 0.222 mmol) in THF (2 mL) at 0° C. was added LiBH₄ (0.222 mL, 0.444 mmol, 2 M in THF). The reaction mixture was stirred at 0° C. for 1 h before quenched with saturated NH₄Cl solution and extracted with EtOAc. The organic layer was washed with brine, dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, dichloromethane/methanol) to give the desired compound as yellow gum (115 mg, 81%). ESI-MS m/z=536.02, 538.02 [M+H]⁺.

Step 25c.

A solution of the compound from step 25b (115 mg, 0.181 mmol), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (66 mg, 0.271 mmol), and sodium bicarbonate (61 mg, 0.722 mmol) in dioxane (1.5 ml) and water (0.500 ml) was degassed by bubbling nitrogen, followed by the addition of Pd(PPh₃)₄ (31 mg, 0.027 mmol). The reaction mixture was heated at 140° C. with a microwave reactor for 30 minutes. The reaction mixture was diluted with DCM, water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, dichloromethane/methanol) to give the desired compound as yellow gum (100 mg, 96%). ESI-MS m/z=574.15, 576.14 [M+H]⁺.

Step 25d.

To a solution of the compound from step 25c (100 mg, 0.174 mmol) in dichloromethane (1.5 ml) at 0° C. was added DMAP (64 mg, 0.523 mmol) and MsCl (0.027 mL, 0.348 mmol) in one portion. The reaction mixture was warmed to 35° C. for 2 h. The reaction mixture was allowed to cool to rt. The reaction mixture was diluted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the title compound as yellow gum (8 mg, 8%). ESI-MS m/z=556.14, 558.13 [M+H]⁺.

Step 26a.

To a solution of Intermediate 1 (5.0 g, 8.84 mmol) and dimethyl malonate (2.03 mL, 17.68 mmol) in acetone (44 mL) was added K₂CO₃ (3.66 g, 26.5 mmol). The reaction mixture was stirred overnight at rt before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the desired compound as a yellow foam (4.89 g, 90%). ESI-MS m/z=615.99, 617.99 [M+H]⁺.

Step 26b.

To a solution of the compound from step 26a (500 mg, 0.811 mmol), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (66 mg, 0.271 mmol), and silver(I) oxide (563 mg, 2.432 mmol) in THF (8 mL) was added Pd(PPh₃)₄ (0.140 g, 0.122 mmol). The reaction mixture was stirred at 70° C. for 18 h. The reaction mixture was filtered through celite, rinsed with EtOAc, and concentrated. The residue was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (252 mg, 48%). ESI-MS m/z=554.19, 556.19 [M+H]⁺.

Step 26c.

To a solution of the compound from step 26b (138 mg, 0.211 mmol) in methanol (3 ml) was added sodium borohydride (80 mg, 2.110 mmol). The reaction mixture was stirred at rt for 3 h. The mixture was diluted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, dichloromethane/methanol) to give the desired compound as yellow gum (81 mg, 64%). ESI-MS m/z=598.16, 600.16 [M+H]⁺.

Step 26d.

To a solution of the compound from step 26c (81 mg, 0.135 mmol) in dichloromethane (1 ml) at rt was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To residue was added DCM (2 mL), MeOH (1 mL) and NaOH (1 mL, 2 M). The mixture was stirred at rt for 2 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the title compound as yellow foam (66 mg, 98%). ESI-MS m/z=498.11, 500.10 [M+H]⁺.

Step 27a.

To a solution of Example 26 (60 mg, 0.121 mmol) and Et₃N (0.084 mL, 0.603 mmol) in DCM (1 mL) at 0° C. was added mesyl chloride (0.145 mL, 0.145 mmol, 1 M in DCM). The reaction mixture was stirred for 3 h at 0° C. before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, dichloromethane/methanol) to give the title compound as yellow film (11 mg, 19%). ESI-MS m/z=480.10, 482.09 [M+H]⁺.

The title compound was isolated from Example 27 (8 mg, 12%). ESI-MS m/z=558.08, 560.07 [M+H]⁺.

Step 29a.

A solution of Example 28 (100 mg, 0.179 mmol) and sodium iodide (27 mg, 0.179 mmol) in acetonitrile (2 mL) and ammonium hydroxide (0.5 mL) was heated at 80° C. for 18 h. The reaction mixture was cooled to rt, diluted with EtOAc, filtered through celite and concentrated to give the crude desired compound as a yellow oil, which was used for next step directly. ESI-MS m/z=479.11, 481.10 [M+H]⁺.

Step 29b.

To a solution of compound from step 29a (43 mg, 0.090 mmol) and Et₃N (0.06 mL, 0.449 mmol) in DCM (2 mL) was added acetic anhydride (0.017 mL, 0.180 mmol). The reaction mixture was stirred at rt for 1h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (11 mg, 24%). ESI-MS m/z=519.09, 521.09 [M+H]⁺.

Step 30a.

To a solution of compound from step 29a (43 mg, 0.090 mmol) and Et₃N (0.06 mL, 0.449 mmol) in DCM (2 mL) was added MsCl (0.18 mL, 0.180 mmol, 1 M in DCM). The reaction mixture was stirred at rt for 1 h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (28 mg, 56%). ESI-MS m/z=557.10, 559.09 [M+H]⁺.

Step 31a.

To a solution of compound from step 29a (50 mg, 0.104 mmol) and Et₃N (0.073 mL, 0.522 mmol) in DCM (2 mL) was added methyl chloroformate (0.016 mL, 0.209 mmol).

The reaction mixture was stirred at rt for 1 h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (29 mg, 52%). ESI-MS m/z=537.13, 539.12 [M+H]⁺.

Step 32a.

To a solution of compound from step 29a (50 mg, 0.104 mmol) and Et₃N (0.073 mL, 0.522 mmol) in DCM (2 mL) was added dimethylcarbamoyl chloride (0.019 mL, 0.209 mmol). The reaction mixture was stirred at rt for 1 h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (28 mg, 49%). ESI-MS m/z=550.14, 552.14 [M+H]⁺.

Step 33a.

To a solution of compound from step 29a (50 mg, 0.104 mmol) and Et₃N (0.073 mL, 0.522 mmol) in DCM (2 mL) was added cyclopropanesulfonyl chloride (29 mg, 0.209 mmol). The reaction mixture was stirred at rt for 1 h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (28 mg, 49%). ESI-MS m/z=583.12, 585.11 [M+H]⁺.

Step 34a.

To a solution of the compound from step 25a (0.75 g, 1.147 mmol) and N-fluorobenzenesulfonimide (0.542 g, 1.720 mmol) in DMF (11.5 mL) was added K₂CO₃ (0.475 g, 3.44 mmol). The reaction mixture was stirred for 1 h at rt before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow oil (700 mg, 91%). ESI-MS m/z=672.15, 674.14 [M+H]⁺.

Step 34b.

To a solution of the compound from step 34a (700 mg, 1.042 mmol) in methanol (10.4 ml) was added sodium borohydride (394 mg, 10.42 mmol). The reaction mixture was stirred at rt for 15 minutes before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was used without further purification (633 mg, 99%). ESI-MS m/z=616.16, 618.15 [M+H]⁺.

Step 34c.

To a solution of the compound from step 34b (633 mg, 1.028 mmol) in dichloromethane (10 ml) at rt was added TFA (2.5 mL, 32.4 mmol). The reaction mixture was stirred at rt for 2 h before being concentrated. To the residue was added DCM (10 mL), MeOH (2 mL) and NaOH (1 mL, 2M). The mixture was stirred at rt for 18 h. It was diluted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow foam (530 mg, 99%). ESI-MS m/z=516.09, 518.08 [M+H]⁺.

Step 34d.

To a solution of the compound from step 34c (530 mg, 1.027 mmol) and Et₃N (1.432 mL, 10.27 mmol) in DCM (10.3 mL) at 0° C. was added mesyl chloride (0.40 mL, 5.14 mmol). The reaction mixture was warmed to rt and stirred for 18h. The reaction was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the title compound as yellow film (86 mg, 15%). ESI-MS m/z=576.07, 578.06 [M+H]⁺.

The title compound was isolated from Example 34 (238 mg, 40%). ESI-MS m/z=576.07, 578.06 [M+H]⁺.

Step 36a.

To a solution of Intermediate 1 (3.0 g, 5.30 mmol) and diethyl 2-methylmalonate (1.81 mL, 10.61 mmol) in acetone (26.5 mL) was added K₂CO₃ (2.20 g, 15.91 mmol). The reaction mixture was stirred overnight at 50° C. before being allowed to cool down, diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the desired compound as a yellow foam (2.21 g, 63%). ESI-MS m/z=660.04, 662.03 [M+H]⁺.

Step 36b.

To a solution of the compound from step 36a (1.90 g, 2.88 mmol), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.056 g, 4.32 mmol), and silver(I) oxide (2.00 g, 8.65 mmol) in THF (29 mL) was added Pd(PPh₃)₄ (0.500 g, 0.432 mmol). The reaction mixture was stirred at 70° C. for 18h. It was filtered through celite, rinsed with EtOAc, and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (1.28 g, 64%). ESI-MS m/z=696.21, 698.21 [M+H]⁺.

Step 36c.

To a solution of the compound from step 36b (1.28 g, 1.839 mmol) in methanol (18 ml) was added sodium borohydride (2.80 g, 73.56 mmol) in 4 evenly divided portions. The reaction mixture was stirred at rt for 3 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, dichloromethane/methanol) to give the desired compound as yellow gum (751 mg, 67%). ESI-MS m/z=612.18, 614.18 [M+H]⁺.

Step 36d.

To a solution of the compound from step 36c (751 mg, 1.227 mmol) in dichloromethane (12 ml) at rt was added TFA (3 mL, 38.9 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To the residue was added DCM (8 mL), MeOH (4 mL) and NaOH (3 mL, 2M). The mixture was stirred at rt for 18 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow foam (617 mg, 98%). ESI-MS m/z=512.11, 514.11 [M+H]⁺.

Step 36e.

To a solution of the compound from step 36d (617 mg, 1.205 mmol) and Et₃N (1.68 mL, 12.05 mmol) in DCM (6 mL) at 0° C. was added mesyl chloride (0.47 mL, 6.03 mmol). The reaction mixture was warmed to rt and stirred for 1 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow film (625 mg, 91%). ESI-MS m/z=572.08, 574.08 [M+H]⁺.

Step 36f.

To a solution of compound from step 36e (350 mg, 0.612 mmol) in DMF (3 mL) was added sodium azide (80 mg, 1.224 mmol). The reaction mixture was heated at 80° C. for 18 h before being allowed to cool down, diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the title compound as a yellow film (30 mg, 10%). ESI-MS m/z=519.10, 521.10 [M+H]⁺.

The title compound was isolated from Example 36. ESI-MS m/z=519.10, 521.10 [M+H]⁺.

Step 38a.

To a solution of Example 36 (20 mg, 0.039 mmol) in MeOH (2 mL) was added Raney nickel (washed with MeOH, 5 mg). The reaction mixture was stirred at rt for 1 h with a hydrogen balloon. It was filtered through celite, washed with EtOAc and concentrated to give the desired compound as a yellow film (19 mg, 99%). ESI-MS m/z=493.12, 495.11 [M+H]⁺.

Step 38b.

To a solution of the compound from step 38a (19 mg, 0.039 mmol) and Et₃N (0.05 mL, 0.359 mmol) in THF (1 mL) was added MsCl (3 μL, 0.039 mmol). The reaction mixture was stirred at rt for 1 h. The reaction mixture was directly chromatographed (silica, hexane/EtOAc/methanol) to give the title compound as yellow film (88 mg, 82%). ESI-MS m/z=571.11, 573.11 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 34. ESI-MS m/z=598.10, 600.10 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 34. ESI-MS m/z=598.10, 600.10 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 36. ESI-MS m/z=523.10, 525.09 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 38. ESI-MS m/z=564.17, 566.16 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 38. ESI-MS m/z=575.08, 577.08 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 38. ESI-MS m/z=568.17, 570.14 [M+H]⁺.

Step 45a.

To a solution of cyclopentanone (0.079 mL, 0.884 mmol) in THF (2 mL) at −78° C. was added LHMDS (0.80 mL, 0.80 mmol, 1M in THF). The reaction mixture was stirred at −78° C. for 1 h. A solution of Intermediate 1 (250 mg, 0.442 mmol) in THF (2 mL) was added. The reaction mixture was allowed to warm up to rt and stirred at rt for 1 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The residue was chromatographed (silica, hexane/ethyl acetate) to give the desired compound as a yellow foam (181 mg, 72%). ESI-MS m/z=467.98, 469.98 [M+H-Boc]⁺.

Step 45b.

To a solution of the compound from step 45a (119 mg, 0.209 mmol), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (77 mg, 0.314 mmol), and silver(I) oxide (145 mg, 0.628 mmol) in THF (2 mL) was added Pd(PPh₃)₄ (36 mg, 0.031 mmol). The reaction mixture was stirred st 70° C. for 1 h before being filtered through celite, rinsed with EtOAc, and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (90 mg, 71%). ESI-MS m/z=606.19, 608.11 [M+H]⁺.

Step 45c.

To a solution of the compound from step 45b (90 mg, 0.742 mmol) in methanol (2 ml) was added sodium borohydride (28 mg, 73.56 mmol). The reaction mixture was stirred at rt for 3 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow film (77 mg, 85%), which was used without further purification. ESI-MS m/z=608.19, 618.12 [M+H]⁺.

Step 45d.

To a solution of the compound from step 45c (77 mg, 0.127 mmol) in dichloromethane (2 ml) at rt was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To the residue was added DCM (8 mL), MeOH (4 mL) and NaOH (3 mL, 2M). The reaction mixture was stirred at rt for 18 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, dichloromethane/MeOH) to give the title compound as yellow foam (617 mg, 98%). ESI-MS m/z=512.11, 514.11 [M+H]⁺.

The title compound was prepared following a similar procedure as Example 45. ESI-MS m/z=568.17, 570.14 [M+H]⁺.

To a solution of Example 45 (617 mg, 1.205 mmol) and Et₃N (1.68 mL, 12.05 mmol) in DCM (6 mL) at 0° C. was added mesyl chloride (0.47 mL, 6.03 mmol). The reaction mixture was allowed to warm up to rt and stirred at rt for 1 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc/MeOH) to give the desired compound as yellow film (0.8 mg, 3%). ESI-MS m/z=572.08, 574.08 [M+H]⁺.

Step 48a.

A solution of the compound from step 26a (4.93 g, 7.99 mmol), 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (2.93 g, 12.0 mmol), Pd(OAc)₂ (90 mg, 0.40 mmol), S-Phos (328 mg, 0.799 mmol) and potassium phosphate (3.39 g, 16.0 mmol) in THF/water (20 mL/1 mL) at rt was degassed and stirred at rt under N₂ for 18 h. The reaction mixture was diluted with EtOAc, washed with water ans brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (5.0 g, 96%). ESI-MS m/z=654.16, 656.16 [M+H]⁺.

Step 48b.

To a solution of the compound from step 48a (1.5 g, 2.293 mmol) in THF (8 ml) was added NaH (0.11 g, 60% in mineral oil, 2.75 mmol) at 0° C. After 30 mins at rt, p-toluenesulfonyl azide (5.35 g, 11% solution in toluene, 2.98 mmol) was added. The reaction mixture was stirred at 60° C. for 18 h. It was diluted with MBTE, filtered through celite and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow gum (1.4 g, 88%). ESI-MS m/z=695.16, 697.16 [M+H]⁺.

Step 48c.

To a solution of the compound from step 48b (1.4 g, 2.01 mmol) in methanol (15 ml) at 0° C. was added sodium borohydride (0.38 g, 10.5 mmol) portionwise. The reaction mixture was stirred at 0° C. for 3 h. It was quenched with saturated aqueous NH₄Cl solution, extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give the desired compound as yellow gum (1.21g, 94%). ESI-MS m/z=639.16, 641.16 [M+H]⁺.

Step 48d.

To a solution of the compound from step 48c (42 mg, 0.066 mmol) in dichloromethane (1 ml) at 0° C. was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To the residue was added DCM (2 mL), MeOH (1 mL) and NaOH (1 mL, 2M). The mixture was stirred at rt overnight before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow foam (66 mg, 98%). ESI-MS m/z=498.11, 500.10 [M+H]⁺.

Step 48e.

To a solution of the compound from step 48d (40 mg, 0.074 mmol) and Et₃N (0.041 mL, 0.297 mmol) in DCM (1 mL) at 0° C. was added mesyl chloride (0.0087 mL, 0.11 mmol). The reaction mixture was stirred at rt for 16 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) and then purified by prep-HPLC (C18 column, acetonitrile/water) to give the tentatively assigned title compound (4.7 mg, 12%). ESI-MS m/z=521.08, 523.08 [M+H]⁺.

The tentatively assigned title compound was isolated from Example 48 (1.0 mg, 2.2%). ESI-MS m/z=599.07, 601.07 [M+H]⁺.

The tentatively assigned title compound was isolated from Example 48 (2.2 mg, 5.7%). ESI-MS m/z=521.08, 523.08 [M+H]⁺.

The tentatively assigned title compound was isolated from Example 48 (1.0 mg, 2.2%). ESI-MS m/z=599.07, 601.07 [M+H]⁺.

To a solution of the compound from example 49 (167 mg, 0.279 mmol) in DMF (1.5 mL) was added sodium azide (36 mg, 0.558 mmol). The reaction mixture was heated at 80° C. for 18 h before being allowed to cool down, diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/ethyl acetate) to give the tentatively assigned title compound as a yellow film (70 mg, 46%). ESI-MS m/z=546.09, 548.09 [M+H]⁺.

To a solution of compound from example 51 (270 mg, 0.451 mmol) in DMF (2.0 mL) was added sodium azide (58.6 mg, 0.901 mmol). The reaction mixture was heated at 80° C. for 18 h before being allowed to cool down, diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/ethyl acetate) to give the tentatively assigned title compound as a yellow film (133 mg, 54%). ESI-MS m/z=546.09, 548.09 [M+H]⁺.

Step 54a.

To a solution of the compound from step 48c (256 mg, 0.40 mmol) in dichloromethane (1.5 ml) at 0° C. was added pyridine (0.097 mL, 1.2 mmol) and methyl chloroformate (0.037 mL, 0.48 mmol). The reaction mixture was stirred at rt for 16 h. It was diluted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow oil (156 mg, 56%). ESI-MS m/z=697.17, 699.17 [M+H]⁺.

Step 54b.

To a solution of the compound from step 54a (150 mg, 0.066 mmol) in dichloromethane (2 ml) at 0° C. was added TFA (1.0 mL). The reaction mixture was stirred at rt for 1 h before being concentrated. To the residue was added DCM (2 mL), MeOH (1 mL) and NaOH (1 mL, 2M). The reaction mixture was stirred at rt overnight before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow foam (128 mg, 100%). ESI-MS m/z=597.11, 599.11 [M+H]⁺.

Step 54c.

To a solution of the compound from step 54b (128 mg, 0.214 mmol) and Et₃N (0.146 mL, 1.07 mmol) in DCM (2 mL) at 0° C. was added mesyl chloride (0.033 mL, 0.429 mmol). The reaction mixture was stirred at rt for 16 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give tentatively assigned title compound (40 mg, 32%). ESI-MS m/z=579.10, 581.10 [M+H]⁺.

The tentatively assigned title compound was isolated from Example 54 (46 mg, 37%). ESI-MS m/z=579.10, 581.10 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=613.12, 611.11 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 10. ESI MS m/z=587.10, 589.09 [M+H]⁺.

The tentatively assigned title compound was prepared following the similar procedure as Example 54. ESI-MS m/z=563.10, 565.10 [M+H]⁺.

The tentatively assigned title compound was isolated from Example 58. ESI-MS m/z=563.10, 565.10 [M+H]⁺.

The title compound was prepared following similar procedure as Example 55. ESI MS m/z=579.09, 581.09 [M+H]⁺.

To a solution of Example 60 (1.450 g, 2.505 mmol) in THF (50 ml) and water (12.50 ml) at rt was added trimethylphosphine (1.0 M in THF, 12.52 ml, 12.52 mmol) dropwise. The mixture was stirred at rt for 1 h before being concentrated by rotavapor. The residue was taken up in 1,4-dioxane (31.3 ml) and water (31.3 ml). Sodium bicarbonate (3.16 g, 37.6 mmol) was added. The mixture was stirred at 90° C. overnight before being allowed to cool down and concentrated. It was diluted with DCM and water. The aqueous layer was back-extracted with DCM (*2). The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.660, 48%) as yellow solid. ESI MS m/z=553.10, 555.10 [M+H]⁺.

Step 62a.

To a solution of Intermediate 1 (100 g, 176 mmol) and 3-(tert-butyl) 4-methyl (2R,4S)-2-(tert-butyl)oxazolidine-3,4-dicarboxylate (83% purity, 73 g, 211 mmol) in THF (250 mL) and DMPU (100 mL) cooled to −40° C. under N₂ was added LiHMDS (1 M in THF, 299 mL, 299 mmol) in 20 min with stirring. The reaction mixture was stirred at −40° C. for 0.5 hours before being quenched by H₂O (100 mL) at −40° C. and allowed to warm up to 10° C. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with H₂O (*1), brine (*1), dried over Na₂SO₄ (s), filtered, and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (116 g, 86% purity, 80% yield) as yellow solid. ESI MS m/z=771.30, 773.30 [M+H]⁺.

Step 62b.

To a solution of the compound from Step 62a (116 g, 86% purity, 129 mmol) and 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (47.2 g, 193 mmol) in THF (500 mL) under Ar at rt was added a solution of K₃PO₄ (54.7 g, 258 mmol) in H₂O (125 mL) and (DTBPF)PdCl₂ (4.2 g, 6.45 mmol). The reaction mixture was degassed and heated at 50° C. for 3 h under Ar before being allowed to cooled down to rt. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with H₂O (*1), brine (*1), dried over Na₂SO₄ (s), filtered, and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (92.0 g, 86%) as yellow solid. ESI MS m/z=809.40, 811.40 [M+H]⁺.

Step 62c.

To a solution of the compound from Step 62b (3.000 g, 3.71 mmol) in acetonitrile (30 ml) at rt was added boron trifluoride etherate (2.349 ml, 18.53 mmol) dropwise. The mixture was stirred at rt for 5 h. Water (3 ml) was added at 0° C. to quench the reaction. The mixture was allowed to warm up to rt. 1 N HCl solution (20 ml) was added at rt. The clear yellow solution was stirred at rt overnight before being concentrated by rotavapor. The aqueous residue was diluted with MTBE and 1 N HCl solution. The organic layer was extracted with 1 N HCl solution (*2). The combined aqueous layers were basicified to pH ˜8 with saturated K₂CO₃ solution, extracted with DCM (*4). The combined DCM extract was dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the title compound (2.000 g, 100%) as a yellow solid. ESI MS m/z=541.10, 543.10 [M+H]⁺.

To a solution of Example 62 (0.200 g, 0.370 mmol) in TH (4 ml) at 0° C. was added a solution of Boc-anhydride (0.094 ml, 0.407 mmol) in THF (1 ml) dropwise. After 10 min at 0° C., the cooling bath was removed and the mixture was stirred at rt overnight. The mixture was concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.206 g, 87%) as yellow solid. ESI MS m/z=641.16, 643.15 [M+H]⁺.

To a solution of Example 63 (0.103 g, 0.161 mmol) in DCM (4 ml) at 0° C. was added triethylamine (0.112 ml, 0.803 mmol), followed by a solution of Ms-Cl (0.025 ml, 0.321 mmol) in DCM (0.15 ml) dropwise. The mixture was stirred at 0° C. for 1 h. The mixture was allowed to warm up and stirred at 40° C. for 10 h. Excess i-PrOH was added. The mixture was concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.206 g, 87%) as yellow solid. ESI MS m/z=623.14, 625.14 [M+H]⁺.

The title compound was prepared following similar procedure as Example 64. ESI MS m/z=623.13, 625.13 [M+H]⁺.

To a solution of Example 64 (1.360 g, 2.183 mmol) in DCM (25 ml) at rt was added 4 M HCl in 1,4-dioxane (10.91 ml, 43.7 mmol) dropwise. The mixture was stirred at rt for 3 h. LC-MS showed almost no SM left. The cloudy mixture was poured into a mixture of DCM and saturated NaHCO₃ solution with some 30% K₂CO₃ solution added. The aqueous layer was extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the desired compound (1.270 g, 100%) as yellow solid. ESI MS m/z=523.10, 525.09 [M+H]⁺.

To a solution of Example 66 (35.3 mg, 0.0675 mmol) in DCM (1.5 ml) at 0° C. was added triethylamine (0.028 ml, 0.203 mmol), followed by a solution of Ms-Cl (7.89 μl, 0.101 mmol) in DCM (0.1 ml) dropwise. The mixture was stirred at 0° C. for 1 h. Excess IPA was added to quench the reaction. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (30.2 mg, 74%) as yellow solid. ESI MS m/z=601.07, 603.06 [M+H]⁺.

The title compound was prepared following similar procedure as Example 67. ESI MS m/z=627.08, 629.08 [M+H]⁺.

To a solution of Example 67 (28.0 mg, 0.047 mmol) in MTBE (2 ml) at 0° C. was added LiBH₄ (2 M in THF, 0.035 ml, 0.070 mmol). The mixture was stirred at 0° C. for 1 h. Saturated NH₄Cl solution was added to quench the reaction. The mixture was diluted with EtOAc. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (17.6 mg, 66%) as yellow solid. ESI MS m/z=573.07, 575.07 [M+H]⁺.

The title compound was prepared following similar procedure as Example 69. ESI MS m/z=599.09, 601.08 [M+H]⁺.

Step 71a.

To a solution of Example 61 (0.040 g, 0.072 mmol) in THF (1.5 ml) at rt was added pyridine (0.018 ml, 0.217 mmol), followed by 4-nitrophenyl chloroformate (0.022 g, 0.109 mmol). The resulting yellow suspension was stirred at rt for 1.5 h. More 4-nitrophenyl chloroformate (0.022 g, 0.109 mmol) was added. The suspension was stirred at rt for 1.5 h. LC-MS showed complete reaction. The suspension was used directly for next step. ESI MS m/z=718.39, 720.39 [M+H]⁺.

Step 71b.

To a half of the suspension from step 71a (0.036 mmol) at rt was added methylamine (2 M in THF, 0.180 ml, 0.360 mmol). The suspension was stirred at rt for 0.5 h before being concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (15.0 mg, 68%) as yellow solid. ESI MS m/z=610.37, 612.37 [M+H]⁺.

To a solution of Example 66 (0.761 g, 1.455 mmol) in DCM (30 ml) at 0° C. was added pyridine (0.353 ml, 4.37 mmol), followed by methyl chloroformate (0.147 ml, 1.892 mmol) dropwise. The mixture was stirred at 0° C. for 1 h. Excess MeOH was added to quench the reaction. After 10 min at rt, the mixture was concentrated by rotavapor. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (0.705 g, 83%) as yellow solid. ESI MS m/z=581.34, 583.34 [M+H]⁺.

To a solution of Example 72 (40.0 mg, 0.069 mmol) in THF (0.75 ml) and MeOH (0.750 ml) at rt was added a solution of LiOH (9.89 mg, 0.413 mmol) in Water (0.225 ml). The mixture was stirred at rt overnight. 0.5 N HCl solution was added to quench the reaction. The mixture was diluted with DCM and water until aqueous layer pH ˜2. The aqueous layer was extracted with DCM (*2). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the title compound (40.0 mg, 100%) as yellow solid. ESI MS m/z=567.32, 569.32 [M+H]⁺.

To a solution of Example 73 (19.56 mg, 0.0345 mmol) and glycine methyl ester hydrochloride (6.50 mg, 0.052 mmol) in DMF (1 ml) at rt was added DIPEA (0.018 ml, 0.104 mmol), followed by HATU (14.43 mg, 0.038 mmol). The mixture was stirred at rt for 3 h before being freed of volatiles with a stream of N₂. The residue was dried under vacuum to afford the title compound (22.0 mg, 100%) as yellow solid. ESI MS m/z=638.36, 640.36 [M+H]⁺.

The title compound was prepared following similar procedure as Example 66. ESI MS m/z=523.10, 525.09 [M+H]⁺.

To a half of the suspension from step 71a (0.036 mmol) at rt was added glycine methyl ester hydrochloride (22.60 mg, 0.180 mmol), followed by DIPEA (0.063 ml, 0.360 mmol). The suspension was stirred at rt for 2 h before being concentrated. The residue was taken up in DCM and filtered through a short pad of celite. The filtrate was directly chromatographed (silica, Hexanes/EtOAc) to give the title compound (8.0 mg, 33%) as yellow solid. ESI MS m/z=668.39, 670.39 [M+H]⁺.

The title compound was prepared following similar procedure as Example 76. ESI MS m/z=682.4136, 65684.4036 [M+H]⁺.

The title compound was prepared following similar procedure as Example 73. ESI MS m/z=68.34, 68470.3 [M+H]⁺.

The title compound was prepared following similar procedure as Example 73. ESI MS m/z=668.39, 670.39 [M+H]⁺.

The title compound was prepared following similar procedure as Example 74. ESI MS m/z=694.44, 696.44 [M+H]⁺.

A solution of Example 80 (8.0 mg, 0.012 mmol) in DCM (0.5 ml) and TFA (0.5 ml) was stirred at rt for 2 h before being concentrated. The residue was dried by lypholization to afford the title compound (7.0 mg, 95%) as yellow solid. ESI MS m/z=638.37, 640.37 [M+H]⁺.

The title compound was prepared following similar procedure as Example 72. ESI MS m/z=581.33, 583.33 [M+H]⁺.

To a solution of Example 61 (0.010 g, 0.018 mmol) in DCM (1 ml) at rt was added pyridine (7.31 μl, 0.090 mmol), followed by acetic anhydride (2.56 μl, 0.027 mmol). The resulting yellow solution was stirred at rt for 0.5 h. Acetyl chloride (1.929 μl, 0.027 mmol) was added at rt. The yellow solution was stirred at rt overnight. Excess i-PrOH was added to quench the reaction. After 10 min at rt, the mixture was freed of volatiles. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (7.0 mg, 65%) as yellow solid. ESI MS m/z=595.35, 597.35 [M+H]⁺.

To a solution of Example 82 (0.265 g, 0.456 mmol) in MeOH (5 ml) at 0° C. was added sodium borohydride (0.035 g, 0.912 mmol). The mixture was stirred at 0° C. for 1 h. More sodium borohydride (0.035 g, 0.912 mmol) was added at 0° C. The mixture was stirred at 0° C. for 1 h. Saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.193 g, 77%) as yellow solid. ESI MS m/z=553.10, 555.10 [M+H]⁺.

To a solution of Example 61 (0.020 g, 0.036 mmol) in DCM (1 ml) at rt was added proton sponge (9.30 mg, 0.043 mmol), followed by trimethyloxonium tetrafluoroborate (5.88 mg, 0.040 mmol). The resulting solution was stirred at rt overnight. More proton sponge (9.30 mg, 0.043 mmol) and trimethyloxonium tetrafluoroborate (5.88 mg, 0.040 mmol) were added. The resulting solution was stirred at rt for 3 h. Saturated NH₄Cl solution was added to quench the reaction. The mixture was diluted with DCM and water. The aqueous layer was back-extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) followed by an citric acid wash to give the title compound (2.0 mg, 10%) as yellow solid. ESI MS m/z=567.34, 569.34 [M+H]⁺.

To a solution of Example 84 (0.193 g, 0.349 mmol) in DMSO (6 ml) at rt was added IBX (0.293 g, 1.047 mmol). The mixture was stirred at rt overnight. Saturated Na₂S₂O₃ solution was added to quench the reaction. The mixture was diluted with EtOAc and water. The organic layer was washed with saturated Na₂S₂O₃ solution (*1), water (*2), brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to give the title compound (0.160 g, 83%) as yellow solid. ESI MS m/z=551.09, 553.09 [M+H]⁺.

To a solution of Example 86(25 mg, 0.045 mmol) in THF (1 ml) at −78° C. was added methylmagnesium bromide (3 M in ether, 0.061 ml, 0.182 mmol) dropwise. The mixture was stirred at −78° C. for 0.5 h. Saturated NH₄Cl solution was added to quench the reaction. The mixture was allowed to warm up to rt and diluted with DCM and water. The aqueous layer was back-extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (10.0 mg, 39%) as yellow solid. ESI MS m/z=567.34, 569.33 [M+H]⁺.

The title compound was prepared following similar procedure as Example 87. ESI MS m/z=579.34, 581.34 [M+H]⁺.

CDI (479 mg, 2.96 mmol) was added to a stirred solution of example 62 (1.0 g, 1.85 mmol) in DMF (20 mL) at rt. After 16 h, it was quenched with water, The reaction mixture was extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered, and evaporated under reduced pressure to give the title compound (1.0g, 87%). ESI MS m/z=567.20, 569.20 [M+H]⁺.

To a solution of Example 89 (9.0 g, 15.8 mmol) in MBTE (180 ml) at 0° C. was added lithium borohydride (0.522 g, 23.8 mmol). The mixture was stirred at 0° C. for 1 h and saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (5.5 g, 66%) as yellow solid. ESI MS m/z=539.20, 541.20 [M+H]⁺.

To a solution of Example 90 (73.6 mg, 0.137 mmol) in DMSO (1.5 ml) at rt was added IBX (57.4 mg, 0.205 mmol). The mixture was stirred at rt overnight. Saturated Na₂S₂O₃ solution was added to quench the reaction. The mixture was diluted with EtOAc and water. The organic layer was washed with saturated Na₂S₂O₃ solution (*1), water (*2), brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (18 mg, 24%) as yellow solid. ESI MS m/z=537.28, 539.28 [M+H]⁺.

The title compound was prepared following similar procedure as Example 62. ESI MS m/z=541.10, 543.10 [M+H]⁺.

The title compound was prepared following similar procedure as Example 89. ESI MS m/z=567.20, 569.20 [M+H]⁺.

The title compound was prepared following similar procedure as Example 90. ESI MS m/z=539.20, 541.20 [M+H]⁺.

The title compound was prepared following similar procedure as Example 91. ESI MS m/z=537.28, 539.28 [M+H]⁺.

To a solution of Example 94 (81 mg, 0.15 mmol) in THF (1 ml) at 0° C. was added pyridine (0.0304 ml, 0.376 mmol), followed by methyl chloroformate (0.0175 ml, 0.225 mmol) dropwise. The mixture was stirred at 0° C. for 1 h. Excess MeOH was added to quench the reaction. After 10 min at rt, the mixture was concentrated by rotavapor. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.044 g, 49%) as yellow solid. ESI MS m/z=597.09, 599.09 [M+H]⁺.

To a solution of Example 94 (81 mg, 0.15 mmol) in THF (1 ml) at 0° C. was added pyridine (0.0607 ml, 0.75 mmol), followed by Ac₂O (0.0226 ml, 0.24 mmol) dropwise. The mixture was stirred at 0° C. for 1 h and rt for 30 h. Excess MeOH was added to quench the reaction. After 10 min at rt, the mixture was concentrated by rotavapor. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.087 g, 100%) as yellow solid. ESI MS m/z=581.09, 583.09 [M+H]⁺.

To a solution of Example 94 (81 mg, 0.15 mmol) in THE (1 ml) at 0° C. was added pyridine (0.036 ml, 0.45 mmol), followed by 4-nitrophenyl methyl chloroformate (45 mg, 0.225 mmol) dropwise. The mixture was stirred at 0° C. for 1 h and rt for 3 h. MeNH₂ (0.8 mL 2 M solution in THF, 1.6 mmol) was added to the mixture. After 1 h at rt, the mixture was concentrated by rotavapor. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (0.061 g, 68%) as yellow solid. ESI MS m/z=596.10, 598.10 [M+H]⁺.

Step 99a.

To a solution of Intermediate 1 (100 g, 176 mmol) and 3-(tert-butyl) 4-methyl (2S,4R)-2-(tert-butyl)oxazolidine-3,4-dicarboxylate (83% purity, 73 g, 211 mmol) in THF (250 mL) and DMPU (100 mL) cooled to −40° C. under N₂ was added LiHMDS (1 M in THF, 299 mL, 299 mmol) in 20 min with stirring. The reaction mixture was stirred at −40° C. for 0.5 hours before being quenched by H₂O (100 mL) at −40° C. and allowed to warm up to 10° C. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with H₂O (*1), brine (*1), dried over Na₂SO₄ (s), filtered, and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (119 g, 83% purity, 79% yield) as yellow solid. ESI MS m/z=771.30, 773.30 [M+H]⁺.

Step 99b.

To a solution of the compound from Step 99a (119 g, 83% purity, 127 mmol) and 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (46.7 g, 191 mmol) in THF (500 mL) under Ar at rt was added a solution of K₃PO₄ (53.8 g, 254 mmol) in H₂O (125 mL) and (DTBPF)PdCl₂ (4.13 g, 6.35 mmol). The reaction mixture was degassed and heated at 50° C. for 3 h under Ar before being allowed to cooled down to rt. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with H₂O (*1), brine (*1), dried over Na₂SO₄ (s), filtered, and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (85 g, 83%) as yellow solid. ESI MS m/z=809.40, 811.40 [M+H]⁺.

Step 99c.

To a solution of compound from step 99b (1.0 g, 1.24 mmol) in MBTE (10 ml) at 0° C. was added lithium borohydride (0.11 g, 4.94 mmol). The mixture was stirred at 0° C. for 2 h and saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (0.59 g, 61%) as yellow solid. ESI MS m/z=781.25, 783.25 [M+H]⁺.

Step 99d.

To a solution of compound from step 99c (78 mg, 0.10 mmol) and MeI (0.031 mL, 0.50 mmol) in DMF (1.5 ml) at 0° C. was added NaH (0.012 g 60%, 0.30 mmol). The mixture was stirred at 0° C. for 3 h and saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (80 mg, 100%) as yellow solid. ESI MS m/z=795.26, 797.26 [M+H]⁺.

Step 99e.

To a solution of the compound from step 99d (80 mg, 0.10 mmol) in acetonitrile (1.5 ml) at rt was added boron trifluoride etherate (0.063 ml, 0.50 mmol) dropwise. The mixture was stirred at rt for 5 h. Water (0.1 ml) was added at 0° C. to quench the reaction. The mixture was allowed to warm up to rt. 1 N HCl solution (1 ml) was added at rt. The clear yellow solution was stirred at rt overnight before being concentrated by rotavapor. The aqueous residue was diluted with MTBE and 1 N HCl solution. The organic layer was extracted with 1 N HCl solution (*2). The combined aqueous layers were basicified to pH ˜8 with saturated K₂CO₃ solution, extracted with DCM (*4). The combined DCM extract was dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the desired compound (53 mg, 100%) as a yellow solid. ESI MS m/z=527.19, 529.19 [M+H]⁺.

Step 99f.

CDI (32.4 mg, 0.20 mmol) was added to a stirred solution of the compound from step 99e (52.7 mg, 0.10 mmol) in THF (2.0 mL) at rt. After 16 h, it was quenched with water, The reaction mixture was extracted with EtOAc. The organic layer was washed with brine, dried over Na₂SO₄, filtered, evaporated under reduced pressure, and chromatographed (silica, Hexanes/EtOAc) to give the title compound (46 mg, 83%). ESI MS m/z=553.10, 555.10 [M+H]⁺.

The title compound was prepared following similar procedure as Example 99. ESI MS m/z=579.36, 581.36 [M+H]⁺.

Et₃N (0.022 mL, 0.16 mmol) was added to a stirred solution of the example 95 (65.6 mg, 0.12 mmol) and methoxyamine hydrochloride (15.5 mg, 0.16 mmol) in DCM (1.0 mL) at rt and the mixture was stirred at rt for 1h. The reaction mixture was chromatographed (silica, Hexanes/EtOAc) to give the title compound (42 mg, 61%) as yellow solid. (ESI MS m/z=566.31, 568.31 [M+H]⁺.

The title compound was prepared following similar procedure as Example 101 ESI MS m/z=628.37, 630.37 [M+H]⁺.

To a solution of Example 93 (115 mg, 0.203 mmol) in THF (1.0 ml) at 0° C. was added a solution of LiOH (0.80 mL 0.5 M, 0.40 mmol). The mixture was stirred at 0° C. for 1h. 0.5 N HCl solution was added to quench the reaction. The mixture was diluted with DCM and water until aqueous layer pH ˜2. The aqueous layer was extracted with DCM (*2). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the title compound (100 mg, 89%) as yellow solid. ESI MS m/z=553.29, 555.29 [M+H]⁺.

The title compound was prepared following similar procedure as Example 103 ESI MS m/z=553.29, 555.29 [M+H]⁺.

A solution of example 95 (28 mg, 0.052 mmol) and methyl (triphenyl-phosphoranylidene)acetate (26.2 mg, 0.078 mmol) in toluene (0.5 mL) was stirred at 90° C. for 1h. It was cooled to rt and chromatographed (silica, Hexanes/EtOAc) to give the title compound (24 mg, 78%) as yellow solid. (ESI MS m/z=593.34, 595.34 [M+H]⁺.

A suspension of example 105 (20 mg, 0.034 mmol) and 10% pd/C (30 mg) in EtOAc (1.5 mL) under a hydrogen balloon was stirred at rt for 28 h. It was filtered through celite, concentrated and chromatographed (silica, Hexanes/EtOAc) to give the title compound (9.1 mg, 45%) as yellow solid. (ESI MS m/z=595.35, 597.35 [M+H]⁺.

To a solution of Example 106 (7.0 mg, 0.012 mmol) in THF (0.9 ml) at 0° C. was added a solution of LiOH (0.30 mL 0.5 M, 0.15 mmol). The mixture was stirred at 0° C. for 1h. 0.5 N HCl solution was added to quench the reaction. The mixture was diluted with DCM and water until aqueous layer pH ˜2. The aqueous layer was extracted with DCM (*2). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was dried under vacuum to afford the title compound (4.1 mg, 60%) as yellow solid. ESI MS m/z=581.34, 583.34 [M+H]⁺.

To a solution of Example 93 (101 mg, 0.178 mmol) in THF (2 ml) at −50° C. was added methylmagnesium bromide (3 M in ether, 0.238 ml, 0.713 mmol) dropwise. The mixture was stirred at rt for 5 h. Saturated NH₄Cl solution was added to quench the reaction. The mixture was allowed to warm up to rt and diluted with DCM and water. The aqueous layer was back-extracted with DCM (*1). The combined organic layers were dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the title compound (28 mg, 28%) as yellow solid. ESI MS m/z=551.31, 553.31 [M+H]⁺.

The title compound was isolated from Example 108. ESI-MS m/z=567.34, 569.34 [M+H]⁺.

To a solution of Example 108 (0.028 g, 0.051 mmol) in MeOH (2 ml) at 0° C. was added sodium borohydride (0.0096 g, 0.254 mmol). The mixture was stirred at 0° C. for 1 h. Saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was purified by prep-HPLC (C18 column, acetonitrile/water) to give title compound (10 mg, 35%). ESI-MS m/z=553.10, 555.10 [M+H]⁺.

Step 111a.

A solution of the compound from step 26a (22.5 g, 36.5 mmol), 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (13.1 g, 54.7 mmol), Pd(OAc)₂ (0.409 g, 1.82 mmol), S-Phos (1.49 g, 3.65 mmol) and potassium phosphate (15.5 g, 72.9 mmol) in THF-water (100 mL/20 mL) at rt was degassed and stirred at rt under N₂ for 18h. It was diluted with EtOAc, washed with water, brine, dry over Na₂SO₄, filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (23.0 g, 96%). ESI-MS m/z=654.13, 656.13 [M+H]⁺.

Step 111b.

To a solution of compound from step 111a (6.38 g, 9.75 mmol) and 3-phenyl-2-(phenylsulfonyl)-1,2-oxaziridine (2.93 g, 11.2 mmol) in THF (100 mL) at −78° C. under N₂ was added LDA (1 M in THF/hexanes, 11.7 mL, 11.7 mmol). The reaction mixture was stirred at −78° C. for 1 hour before being quenched by sat. aqueous NH₄Cl at −78° C. and being allowed to warm up to rt. The reaction mixture was partitioned between EtOAc and water. The organic layer was washed with H₂O (*1), brine (*1), dried over Na₂SO₄ (s), filtered, and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (6.1 g, 93%) as yellow solid. ESI MS m/z=670.14, 672.14 [M+H]⁺.

Step 111c.

A solution of the compound from step 111b (3.3 g, 4.92 mmol) in methanol (20 ml) at 0° C. was added sodium borohydride (1.49g, 39.4 mmol) portionwise. It was stirred at 0° C. for 0.5 h then rt for 3h. The reaction was quenched with sat. aqueous NH₄Cl solution, extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give the desired compound as yellow gum (0.86g, 28%). ESI-MS m/z=614.14, 616.14 [M+H]⁺.

Step 111d.

To a solution of the compound from step 111c (95 mg, 0.155 mmol) in dichloromethane (2 ml) at rt was added TFA (2.0 mL, 27.5 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To residue was added DCM (2 mL), MeOH (1 mL) and NaOH (1 mL, 2 M). The mixture was stirred at rt for 2 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated and purified by prep-HPLC (C18 column, acetonitrile/water) to give title compound (16 mg, 20%). ESI-MS m/z=514.09, 516.09 [M+H]⁺.

Step 112a.

A solution of the compound from step 111b (3.3 g, 4.92 mmol) in methanol (20 ml) at 0° C. was added sodium borohydride (1.49g, 39.4 mmol) portionwise. It was stirred at 0° C. for 0.5 h then rt for 3h. The reaction was quenched with sat. aqueous NH₄Cl solution, extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give the desired compound as yellow gum (1.19g, 37%). ESI-MS m/z=642.13, 644.13 [M+H]⁺.

Step 112b.

To a solution of the compound from step 112a (0.93 g, 0.155 mmol) in dichloromethane (4 ml) at rt was added TFA (4.0 mL, 55 mmol). The reaction mixture was stirred at rt for 1 h before being concentrated. To residue was added DCM (8 mL), MeOH (4 mL) and NaOH (4 mL, 2 M). The mixture was stirred at rt for 2 h before being diluted with EtOAc and washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated and chromatographed (silica, hexanes/EtOAc) to give the title compound (0.59g, 75%). ESI-MS m/z=542.09, 544.09 [M+H]⁺.

Step 113a.

To a solution of the compound from step 111c (0.86 g, 1.40 mmol) and Et₃N (0.64 g mL, 6.3 mmol) in DCM (5.0 mL) at 0° C. was added mesyl chloride (0.35g, 3.08 mmol). The reaction mixture was stirred for 1h at 0° C. The reaction was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give desired compound (1.07g, 99%). MS m/z=720.08, 722.08 [M+H]⁺.

Step 113b.

To a solution of the compound from step 113a (1.07 g, 1.39 mmol) in dichloromethane (5 ml) at 0° C. was added TFA (5 mL, 64.9 mmol). It was stirred at rt for 1h. The reaction mixture was then concentrated. To the reaction mixture was added DCM (2 mL), MeOH (1 mL) and NaOH (1 mL, 2M), extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated to give the desired compound as yellow foam (0.86 mg, 92%). ESI-MS m/z=670.04, 672.03 [M+H]⁺.

Step 113c.

A suspension of compound from step 113b (0.86 g, 1.28 mmol) and K₂CO₃ (0.88g, 6.42 mmol) in DMF (5 mL) was stirred at rt for 5h. It was diluted with EtOAc, washed with water, brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexanes/EtOAc) to give desired compound (0.50g, 82%). MS m/z=478.08, 480.08 [M+H]⁺.

Step 113d.

A suspension of compound from step 113c (0.50 g, 1.05 mmol), NH₄Cl (0.28g, 5.23 mmol) and sodium azide (0.34g, 5.23 mmol) in DMF (5 mL) was stirred at 72° C. for 18h. The reaction was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/ethyl acetate) to to give a title compound (0.32 g, 59%) ESI-MS m/z=21.08, 523.08 [M+H]⁺.

A suspension of compound from step 113c (0.50 g, 1.05 mmol), NH₄Cl (0.28g, 5.23 mmol) and sodium azide (0.34g, 5.23 mmol) in DMF (5 mL) was stirred at 72° C. for 18h. The reaction was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, hexane/ethyl acetate) to to give a title compound (0.22 g, 41%). ESI-MS m/z=521.08, 523.08 [M+H]⁺.

Step 115a.

To a solution of example 114 (105 mg, 0.202 mmol) in THF-water (1.8/0.2 mL) was added ph3P (132 mg, 0.504 mmol) at rt. After being stirred at rt for 18 h and 60° C. for 1h, The mixture was concentrated under vacuum to give the desired crude amine. ESI-MS m/z=495.10, 497.10 [M+H]⁺.

Step 115b.

To a solution of compound from step 115a (20 mg, 0.040 mmol) and Et₃N (0.017 mL, 0.12 mmol) in THF-water (0.36/0.4 mL) was MsCl (0.0063 mL, 0.080 mmol) at 0° C. and stirred for 30 mins. The mixture was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was purified by prep-HPLC (C18 column, acetonitrile/water) to give title compound (10.7 mg, 46%). ESI-MS m/z=573.07, 575.07 [M+H]⁺.

To a solution of compound from step 115a (25 mg, 0.051 mmol) and pyridine (0.061 mL, 0.76 mmol) in THF-water (0.36/0.4 mL) was Ac₂O (0.024 mL, 0.25 mmol) at 0° C. and stirred for 1 h at rt. The mixture was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, DCM/MeOH) to to give a title compound (19 mg, 70%). ESI-MS m/z=537.11, 539.11 [M+H]⁺.

To a solution of compound from step 115a (25 mg, 0.051 mmol) and pyridine (0.061 mL, 0.76 mmol) in THF-water (0.36/0.4 mL) was methyl chloroformate (0.020 mL, 0.25 mmol) at 0° C. and stirred for 1 h at rt. The mixture was extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was chromatographed (silica, Hexanes/EtOAc) to to give a title compound (20 mg, 71%). ESI-MS m/z=553.10, 555.10 [M+H]⁺.

The title compound was prepared following similar procedure as Example 115 ESI MS m/z=573.07, 575.07 [M+H]⁺.

The title compound was prepared following similar procedure as Example 87. ESI MS m/z=567.34, 569.33 [M+H]⁺.

To a solution of Example 112 (0.59 g, 1.09 mmol) in DCM (4 ml) at 0° C. was added triethylamine (0.759 ml, 5.44 mmol), followed by a solution of Ms-Cl (0.093 ml, 1.19 mmol) in DCM (0.2 ml) dropwise. The mixture was stirred at 0° C. for 1 h. The mixture was allowed to warm up and stirred at rt for 20 h. Excess i-PrOH was added. The mixture was concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) and further purified prep-HPLC (C18 column, acetonitrile/water) to give the tentatively assigned title compound (132 mg, 23%). ESI-MS m/z=524.08, 526.08 [M+H]⁺.

The tentatively assigned title compound was isolated from example 120 (96 mg, 17%). ESI MS m/z=524.08, 526.08 [M+H]⁺.

A solution of the compound from example 120 (52 mg, 0.10 mmol) in methanol (2 ml) at 0° C. was added sodium borohydride (23 mg, 0.60 mmol) portionwise. It was stirred at 0° C. for 1 h. The reaction was quenched with sat. aqueous NH₄Cl solution, extracted with EtOAc, washed with water and brine. The organic layer was dried (Na₂SO₄), filtered and concentrated. The crude product was purified prep-HPLC (C18 column, acetonitrile/water) to give tentatively assigned title compound (28 mg, 56%). ESI-MS m/z=496.08, 498.08 [M+H]⁺.

The tentatively assigned title compound was prepared following similar procedure as Example 122 ESI MS m/z=496.08, 498.08 [M+H]⁺.

Step 124a.

To a solution of Intermediate 1 (527 mg, 0.932 mmol) and tert-butyl N-{[(5R)-2-oxo-1,3-oxazolidin-5-yl]methyl}carbamate (168 mg, 0.777 mmol) in DMF (5.0 mL) at 0° C. was added NaH (46.6 mg 60%, 1.16 mmol). The mixture was stirred at 0° C. for 3 h and saturated NH₄Cl solution was added to quench the reaction at 0° C. The mixture was diluted with EtOAc and water and allowed to warm up to rt. The organic layer was washed with brine (*1), dried over Na₂SO₄ (s), filtered and concentrated. The residue was chromatographed (silica, Hexanes/EtOAc) to give the desired compound (0.38 g, 70%) as yellow solid. ESI MS m/z=700.09, 702.09 [M+H]⁺.

Step 124b.

A solution of the compound from step 124a (334 mg, 0.476 mmol), 1-(difluoromethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (174 mg, 0.715 mmol), Pd(OAc)₂ (10.7 mg, 0.048 mmol), S-Phos (39.1 mg, 0.095 mmol) and potassium phosphate (202 mg, 0.953 mmol) in THF-water (2 mL/0.2 mL) at rt was degassed and stirred at rt under N₂ for 18h. It was diluted with EtOAc, washed with water, brine, dry over Na₂SO₄, filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the desired compound as yellow foam (298 mg, 85%). ESI-MS m/z=738.19, 740.19 [M+H]⁺.

Step 124c.

A suspension of the compound from step 124b (47 mg, 0.064 mmol) and sodium bicarbonate (32 mg, 0.382 mmol) in dioxane-water (1 mL/0.35 mL) was stirred 110° C. for 48 h. It was diluted with EtOAc, washed with water, brine, dry over Na₂SO₄, filtered and concentrated. The crude product was chromatographed (silica, hexane/EtOAc) to give the title compound as yellow foam (19 mg, 47%). ESI-MS m/z=638.15, 640.15 [M+H]⁺.

Step 125a.

To a solution of the compound from step 124b (122 mg, 0.165 mmol) in dichloromethane (2 ml) at rt was added 4N HCl in dioxane (2 mL, 8.0 mmol). It was stirred at rt for 14 h. The reaction mixture was then concentrated to give the desired product (99 mg, 98%). ESI-MS m/z=538.10, 540.10 [M+H]⁺.

Step 125b.

To a solution of compound from step 125a (27.5 mg, 0.045 mmol) in DCM-MeOH (0.8/0.2 mL) at 0° C. was added triethylamine (0.063 ml, 0.45 mmol), followed by a methyl chloroformate (0.021 ml, 0.27 mmol). The mixture was stirred at 0° C. for 1 h. It was diluted with EtOAc, washed with water, brine, dry over Na₂SO₄, filtered and concentrated.

The crude product was chromatographed (silica, hexane/EtOAc) to give the title compound as yellow foam (26 mg, 97%). ESI-MS m/z=596.11, 598.11 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=610.12, 612.12 [M+H]⁺.

The title compound was prepared following similar procedure as Example 124. ESI MS m/z=638.15, 640.15 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=596.11, 598.11 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=610.12, 612.12 [M+H]⁺.

The title compound was prepared following similar procedure as Example 124. ESI MS m/z=636.17, 638.17 [M+H]⁺.

The title compound was prepared following similar procedure as Example 124. ESI MS m/z=636.17, 638.17 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=594.13, 596.12 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=594.13, 596.12 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=608.14, 610.14 [M+H]⁺.

The title compound was prepared following similar procedure as Example 125. ESI MS m/z=608.14, 610.14 [M+H]⁺.

Step 136a.

To a stirred mixture of Intermediate 1 (4.0g, 7.08 mmol, 1.0 eq.) and dimethyl 2-fluoromalonate (2.12 g, 14.12 mmol, 2.0 eq.) in DMF (30 mL) was added NaH (850 mg, 21.25 mmol, 3.0 eq., 60%) in portions at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched by addition of aqueous NH₄Cl solution. Then the mixture was extracted with EtOAc. The combined organic phases were washed with brine, dried over Na₂SO₄. and concentrated under reduced pressure. The crude product was purified by silica gel column with EtOAc/hexanes (1/5) to give the desired product(3.4 g, 75.7%) as a yellow solid.

Step 136b.

To a stirred mixture of the compound from Step 136a. (2.80 g, 4.41 mmol, 1.0 eq.) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.61 g, 6.60 mmol, 1.5 eq.) in THF (30 mL) was added a solution of K₃PO₄ (1.87 g, 8.82 mmol, 2.0 eq.) in H₂O (30 mL) and [1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (287 mg, 0.44 mmol, 0.1 eq.) at room temperature. Then the reaction mixture was stirred at 50° C. for 4 h. The reaction was cooled to room temperature and the organic layer was separated and concentrated under reduced pressure. The crude product was purified by silica gel column with EtOAc/hexanes (1/3) to give the desired product (2.80g, 94.5%) as red solid.

Step 136c.

To a stirred mixture of the compound from Step 136b (2.80 g, 4.17 mmol, 1.0 eq.) in MeOH (30 mL) was added NaBH₄ (788 mg, 20.83 mmol, 5.0 eq.) at 0° C. Then the reaction mixture was stirred for 2 h at room temperature. The reaction was quenched with water. The resulting mixture was extracted with EtOAc and washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column with EtOAc/hexanes (1/1 up to 2/1) to give the desired compound (2.0g, 77.9%) as a yellow solid. ESI MS, m/z=616.10, 618.10 [M+H]⁺.

Step 136d.

To a stirred mixture of the compound from Step 136c (200 mg, 0.33 mmol, 1.0 eq.), (4-fluorophenyl)boronic acid (45 mg, 0.33 mmol. 1.0 eq.) and Cs₂CO₃ (211 mg, 0.65 mmol, 2.0 eq.) in DMF (10 mL) was added CH₃I (69 mg, 0.49 mmol, 1.5 eq.) at room temperature and stirred for 2 days. The resulting mixture was quenched with water and extracted with EtOAc. The organic phase was washed with brine and dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column with EtOAc/hexanes (1/2) to give the desired product (100 mg, 49%) as a yellow solid. ESI MS, m/z=630.20, 632.20 [M+H]⁺.

Step 136e.

To a stirred mixture of the compound from Step 136d (100 mg, 0.16 mmol, 1.0 eq.) in DMF (5 mL) was added NaH (13 mg, 0.53 mmol, 2.0 eq. 60%) at 0° C. The resulting mixture was stirred for 0.5h at room temperature. Then allylbromide (38 mg, 0.32 mmol, 2.0 eq.) was added and the reaction mixture was stirred for another 1 h at room temperature. The reaction was quenched with water and extracted with EtOAc. The EtOAc phase was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by silica gel column with EtOAc/hexanes (1/3) to give the desired product (100 mg, 94%) as yellow solid.

Step 136f.

To a stirred mixture of compound from Step 136e (100 mg, 0.25 mmol, 1.0 eq.) in DCM (2 mL) was added TFA (1 mL) at room temperature. The reaction mixture was stirred at room temperature for 1h. The resulting mixture was concentrated under reduced pressure. This resulting crude product was purified by Prep-HPLC to give the title compound (22.0 mg, 26%) as yellow solid. ESI MS, m/z=570.25, 572.25 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 136. ESI MS m/z=516.05, 518.05 [M+H]⁺.

The title compound was prepared following the similar procedure as Example 136. ESI MS m/z=544.15, 546.15[M+H]⁺.

Step 139a.

To a stirred mixture of the compound from step 136c (150 mg, 0.24 mmol, 1.0 eq.) and acetaldehyde (32 mg, 0.72, 3.0 eq.) in toluene(3 mL) was added TsOH (13 mg, 0.08 mmol, 0.3 eq.) at room temperature. The resulting mixture was stirred for 2 h at 120° C. The resulting mixture was removed under reduced pressure to afford 150 mg of the desired product as a crude product, which was used directly in the next step without further purification.

Step 139 b.

To a stirred mixture of the compound from Step 139a (150 mg, crude) in DCM (2.5 mL) was added TFA (0.5 mL) at room temperature. The resulting mixture was stirred for 1 h at room temperature. The resulting mixture was adjusted to pH=8 with saturated NaHCO₃ aq., extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The residue was purified by Prep-HPLC to afford the title compound (9.7 mg) as a yellow solid. ESI MS m/z=542.05, 544.05 [M+H]⁺.

The title compound (31.2 mg) was also isolated from the Step 139b in Example 139 as a yellow solid. ESI MS m/z=542.05, 544.05 [M+H]⁺.

The title compound (2.9 mg) was prepared following the similar procedure as Example 139. ESI MS m/z=570.10, 572.10[M+H]⁺.

The title compound (20.1 mg) was also isolated from Example 141. ESI MS m/z=570.10, 572.10[M+H]⁺.

The title compound (4.7 mg) was prepared following the similar procedure as Example 139. ESI MS m/z=604.10, 606.10 [M+H]⁺.

The title compound (15.4 mg) was isolated from Example 143. ESI MS m/z=604.20, 606.20 [M+H]⁺.

Step 145a.

To a stirred mixture of Intermediate 1 (500 mg, 0.88 mmol, 1.0 eq.) and cyclopentanethiol (100 mg, 0.98 mmol, 1.11 eq.) in THF (5.00 mL) was added triethylamine (135 mg, 1.33 mmol, 1.5 eq.) at room temperature. The resulting mixture was stirred for 16h at room temperature. The resulting mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with EtOAc/hexanes (1/10 to 1/5) to afford the desired product (337 mg, 65%) as a yellow solid. ESI MS m/z=587.95, 589.95[M+H]⁺.

Step 145b.

To a stirred solution of the compound from Step 145a. (337 mg, 0.57 mmol, 1.0 eq.) in DCM (1 mL) was added m-CPBA (223 mg, 1.15 mmol, 2.0 eq. 85%) in portions at 0° C. The resulting mixture was stirred for 1 h at 0° C. The resulting mixture was diluted with EtOAc (50 mL) and washed with water. The organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/hexanes (1/3) to afford the desired product (308 mg, 86.7%) as a yellow solid. ESI MS m/z=620.00, 622.00 [M+H]⁺.

Step 145c.

To a stirred mixture of the compound from Step 145b (200 mg, 0.32 mmol, 1.0 eq.) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (115 mg, 0.47 mmol, 1.46 eq.) in THF (2 mL) and H₂O (1 mL) were added [1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (21 mg, 0.03 mmol, 0.1 eq.) and K₃PO₄ (134 mg, 0.63 mmol, 2.0 eq.). The resulting mixture was stirred for 2h at 50° C. under nitrogen atmosphere. The resulting mixture was diluted with water (50 mL). The resulting mixture was extracted with EtOAc (2×20 mL). The combined organic layers were washed with brine (1×20 mL), dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The residue was purified by Prep-TLC (EtOAc/hexanes=5/1) to afford the desired product (180 mg, 85%) as a yellow solid. ESI MS m/z=656.15, 658.15[M+H]⁺.

Step 145 d.

To a stirred mixture of the compound from Step 145c. (100 mg, 0.15 mmol, 1.0 eq.) in DCM (2 mL) was added TFA (0.5 mL). The resulting mixture was stirred for 2 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC to afford the title product (27.2 mg, 32.1%) as a yellow solid. 145c. (100 mg, 0.15 mmol, 1.0 eq.) ESI MS m/z=556.10, 558.10 [M+H]⁺.

Step 146a.

To a stirred mixture of Intermediate 1 (500 mg, 0.88 mmol, 1.0 eq.) in EtOH (2 mL) was added a solution of Na₂SO₃ (112 mg, 0.88 mmol, 1.0 eq.) in water (2 mL) at room temperature. The resulting mixture was stirred for 6 h at 50° C. The reaction mixture was concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with DCM/MeOH (5/1) to afford the desired product (413 mg, 82.5%) as a light yellow solid. ESI MS m/z=567.90, 569.90[M+H]⁺.

Step 146b.

To a solution of the compound from Step 146a (200 mg, 0.34 mmol, 1.0 eq.) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (125 mg, 0.51 mmol, 1.5 equiv) in THF (2 mL) and H₂O (0.5 mL) were added K₃PO₄ (144.20 mg, 0.679 mmol, 2 equiv) and [1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (22 mg, 0.03 mmol, 0.1 eq.). After stirring for 6 h at 50° C., the resulting organic layer was concentrated under reduced pressure. The residue was purified by Prep-TLC with MeOH/DCM (1/10) to afford the desired product (135 mg, 65.8%) as a yellow solid. ESI MS m/z=604.05, 606.05 [M+H]⁺.

Step 146c.

To a stirred mixture of the compound from Step 146b (100 mg, 0.17 mmol, 1.0 eq.) in DCM (1 mL) were added oxalic dichloride (63 mg, 0.50 mmol, 3.0 eq.) and DMF (1 drop) at 0° C. The resulting mixture was stirred for 5 h at 0° C. The resulting mixture was concentrated under vacuum to give the desired product (100 mg) as a crude product, which was used directly in next step without further purification.

Step 146d.

To a stirred solution of the compound from Step 146c (100 mg, crude) in DCM (1 mL) was added piperidin-4-ol (50 mg, 0.50 mmol) at room temperature. The resulting mixture was stirred for 3h at room temperature. The resulting mixture was concentrated under reduced pressure. The residue was purified by Prep-TLC (EtOAc/hexanes=1/1) to afford the desired product (70 mg) as a yellow solid. ESI MS m/z=687.05, 689.05 [M+H]⁺.

Step 146e.

To a solution of the compound from Step 146d (60 mg, 0.09 mmol, 1.0 eq.) in DCM (1 mL) was added TFA (0.5 mL) at room temperature. The resulting mixture was stirred for 2h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC to afford the title compound (23.3 mg, 45.5%) as a yellow solid. ESI MS m/z=587.20, 589.20 [M+H]⁺.

Step 147a.

To a solution of ethyl 2,2-difluoro-2-iodoacetate (663 mg, 2.65 mmol, 3.0 eq.) in DMSO (5 mL) was added copper (337 mg, 5.30 mmol, 6.0 equiv). The resulting mixture was stirred for 40 min at room temperature. Intermediate 1 (500 mg, 0.88 mmol, 1.0 eq.) was added and the mixture was stirred for additional 3 h at room temperature. The resulting mixture was diluted with water (50 mL), extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/hexanes (1/5) to give the desired product (187 mg, 34.7%) as a yellow solid. ESI MS m/z=609.90, 611.90 [M+H]⁺.

Step 147b.

To a solution of the compound from Step 147a (150 mg, 0.25 mmol, 1.0 eq.) and 1-(difluoromethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (91 mg, 0.37 mmol, 1.5 eq.) in THF (1.6 mL) and H₂O (0.4 mL) were added K₃PO₄ (105 mg, 0.50 mmol, 2 eq.) and [1,1′-Bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (16 mg, 0.025 mmol, 0.1 eq.). After stirring for 3h at 50° C., the resulting organic layer was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc/hexanes (1/3) to afford the desired product (120 mg, 75.4%) as a yellow solid. ESI MS m/z=646.10, 648.10[M+H]⁺.

Step 147c.

To a stirring solution of the compound from Step 147b (90 mg, 0.14 mmol, 1.0 eq.) in EtOH (1 mL) was added NaBH₄ (11 mg, 0.28 mmol, 2.0 equiv) at 0° C. The resulting mixture was stirred for 1 h at room temperature. The reaction was quenched with water at 0° C. The resulting mixture was extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give the desired product (80 mg) as a crude product, which was used in the next step directly without further purification. ESI MS m/z=604.25, 606.25 [M+H]⁺.

Step 147d.

To a stirred solution of the compound from Step 147c (80 mg, crude) in DCM (0.9 mL) was added TFA (0.3 mL) at room temperature. The resulting mixture was stirred for 1 h at room temperature. The resulting mixture was concentrated under vacuum. The crude product was purified by Prep-HPLC to afford the title compound (53.3 mg) as a yellow solid. ESI MS m/z=504.00, 506.00 [M+H]⁺.

Step 148a.

To a stirred mixture of the compound from Step 136c (300 mg, 0.49 mmol, 1.0 eq.) and TBSCl (73 mg, 0.49 mmol, 1.0 eq.) in DCM (3 mL) was added imidazole(66 mg, 0.98 mmol, 2.0 eq) at room temperature. The resulting mixture was stirred for 16 h at room temperature. The reaction mixture was diluted with water (30 mL), extracted with EtOAc (30 mL×3). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by silica gel column chromatography, eluted with EtOAc/hexanes (1/3 to 2/1) to afford the desired product (200 mg, 56.2%) as a yellow solid. ESI MS m/z=[730.60, 732.60 M+H]⁺.

Step 148b.

To a stirred mixture of the compound from Step 148a (150 mg, 0.20 mmol, 1.0 eq.) in DCM (2 mL) were added MsCl (35 mg, 0.30 mmol, 1.5 eq.) and triethylamine (41 mg, 0.40 mmol, 2.0 eq.) dropwise at room temperature. The resulting mixture was stirred for 2h at room temperature. The resulting mixture was diluted with EtOAc (30 mL), washed with water (2×20 mL), dried over anhydrous Na₂SO₄ and concentrated under vacuum to give the desired product (150 mg) as a crude product, which was used directly in next step directly without further purification. ESI MS m/z=808.20, 810.20 [M+H]⁺.

Step 148c.

To a stirred mixture of the compound from Step 148b (150 mg, crude) in DCM (1 mL) was added TFA (0.5 mL). The resulting mixture was stirred for 1 hour at room temperature. The resulting mixture was concentrated under vacuum. The residue was dissolved in EA (30 mL). The resulting mixture was washed with aqueous NaHCO₃ solution (10 mL), water (2×10 mL) and dried over anhydrous Na₂SO and concentrated under vacuum to give the desired product (110 mg) as a crude product, which was used in next step without further purification. ESI MS m/z=708.15, 710.15 [M+H]⁺.

Step 148d.

To a stirred mixture of the compound from Step 148c (110 mg, crude) in DCM (1 mL) was added TEA (50 mg, 0.50 mmol) at room temperature. The resulting mixture was stirred for 6 h at 40° C. The resulting mixture was diluted with EtOAc (30 mL). The resulting mixture was washed with water (10 mL), dried over anhydrous Na₂SO₄, and concentrated to give the desired product (80 mg) as a crude product, which was used in next step without further purification. ESI MS m/z=612.30, 614.30 [M+H]⁺.

Step 148e.

To a stirred mixture of the compound from Step 148d (80 mg, crude) in THF (1 mL) was added HCl (0.3 mL) at room temperature. The resulting mixture was stirred for 1 hour at room temperature. The resulting mixture was diluted with EtOAc (30 mL), washed with aqueous NaHCO₃ solution (10 mL), water (2×10 mL), dried over anhydrous Na₂SO₄, and concentrated under vacuum. The crude product was purified by Prep-HPLC to give the title compound (15.0 mg) as a yellow solid. ESI MS m/z=498.20, 500.20 [M+H]⁺.

The title compound (28.8 mg) was also isolated from the Step 148e in Example 148 as a yellow solid. ESI MS m/z=498.20, 500.20 [M+H]⁺.

The following examples were prepared by using procedures similar to those described above:

Biological Activity

Methods: HepAD38 cells are maintained as previously reported (Ladner et al, Antimicrob. Agents Chemother. 1997, 4, 1715). Briefly, cells are passaged upon attaining confluency in DMEM/F12 media in the presence of 10% FBS, Penn/Strep, 250 μg/mL G418, and 1 μg/ml tetracycline. Novel compounds are screened by first washing cells three times with PBS to remove tetracycline, and plating in 96 well plates at 35,000 cells/well. Compounds dissolved in DMSO are then diluted 1:200 into wells containing cells. Five days after compound addition, material is harvested for analysis. For an extended 8 day analysis, cells are plated and treated as described above, but media and compound are refreshed on d2 and d5 post initial treatment.

On harvest day, virion DNA is obtained by lysing with Sidestep Lysis and Stabilization Buffer and then quantified via quantitative real time PCR. Commercially available ELISA kits are used to quantitate the viral proteins HBsAg (Alpco) or HbeAg (US Biological) by following the manufacturer's recommended protocol after diluting samples to match the linear range of their respective assays. Irrespective of readout, compound concentrations that reduce viral product accumulation in the cell lysates or supernatants by 50% relative to no drug controls (EC₅₀) are reported; EC₅₀ ranges are as follows: A<0.1 μM; B 0.1-1 μM; C>1 μM.

Compound toxicity is evaluated by seeding cells at 15,000 cells/well and treating with compound as described above. Three days after compound addition, cells are treated with ATPLite reagent and compound concentrations that reduce total ATP levels in wells by 50% relative to no drug controls (CC₅₀) are reported; CC₅₀ ranges are as follows: A>25 μM; B 10-25 μM; C<10 μM.

TABLE 1 Summary of Activities HepAD38 HepG2 Compd. Number EC₅₀ (μM) CC₅₀ (μM) 1 A A 2 B 3 A A 4 >0.1 5 A 6 A A 7 A 8 A B 9 A A 10 A A 11 A A 12 A B 13 A A 14 A 15 >0.1 16 >0.1 17 >0.1 18 A 19 A 20 >0.4 21 A 22 A 23 A 24 A 25 >0.2 26 >0.1 27 >0.1 28 >0.1 29 >0.1 30 >0.1 31 >0.1 32 >0.1 33 >0.1 34 >0.4 35 B 36 >0.4 37 >0.4 38 >0.4 39 >0.4 40 >0.4 41 >0.4 42 >0.4 43 B 44 B 45 B 46 B 47 >0.4 48 >0.4 49 B 50 A 51 B 52 >0.4 53 >0.4 54 >0.4 55 A 56 A A 57 A A 58 >0.4 59 A 61 A A 62 >0.4 63 >0.4 64 >0.4 65 >0.4 67 >0.4 68 >0.4 69 >0.4 70 B 71 >0.4 73 >0.4 74 >0.4 75 >0.4 77 >0.4 78 >0.4 79 >0.4 80 >0.4 81 >0.4 82 >0.4 83 >0.4 84 A 85 >0.4 87 >0.4 88 >0.4 89 >0.4 90 >0.4 91 A 92 >0.4 93 A 94 A A 95 A 96 B 97 B 98 >0.4 99 >0.4 100 >0.4 101 >0.4 102 B 103 >0.4 104 >0.4 105 >0.4 106 >0.4 107 >0.4 108 >0.4 109 >0.4 110 >0.4 111 A 112 >0.4 113 B 114 B 115 >0.4 116 >0.4 117 >0.4 118 >0.4 119 >0.4 120 >0.4 121 >0.4 122 B 123 >0.4 124 >0.4 125 >0.4 126 >0.4 127 >0.4 128 >0.4 129 >0.4 130 >0.4 131 >0.4 132 >0.4 133 >0.4 134 >0.4 135 >0.4 136 >0.4 137 B 138 B 139 >0.4 140 B 141 >0.4 142 >0.4 143 >0.4 144 >0.4 145 >0.4 146 >0.4 147 >0.4 148 B 149 B

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. 

1. A compound represented by Formula (IIIa-7), (IIIb-7), (IIIc-7), or (IIId-7),

or a pharmaceutically acceptable salt thereof, wherein: A₁ is a optionally substituted 5-membered heteroaryl group containing 1 to 4 heteroatoms selected from O, N, and S; A₂ is an optionally substituted phenyl, thiophenyl or 6-membered heteroaryl group; X₁ is optionally substituted methyl, halo, CN, OR₁₁, or NR₁₁R₁₂; m is 0, 1, 2, 3, 4 or 5; R₅ is selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)R₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —S(O)₂R₁₁, —S(O)₂NR₁₁R₁₂, and —C(O)NR₁₂S(O)₂R₁₂; and R₁₁, R₁₂ and R₂₀ at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.
 2. The compound of claim 1, represented by Formula (IIIa-8) or (IIIb-8), or a pharmaceutically acceptable salt thereof,

wherein R₅, R₁₁ and R₂₀ are as defined in claim
 1. 3. A compound represented by Formula (Va) or (Vb), or a pharmaceutically acceptable salt thereof,

wherein: X₂ at each occurrence is independently selected from hydrogen or halogen; W is selected from the group consisting of hydrogen, halogen, —CN, —N₃, —OR₁₁, —CR₁₁R₁₂R₃, —NR₁₁R₁₂, protected hydroxy, protected amino, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl, optionally substituted heteroaryl, —C(O)R₁₁, —C(O)OR₁₁, —C(O)NR₁₁R₁₂, —NR₁₁CONR₁₁R₁₂, —S(O)₂R₁₁, —S(O)₂NR₁₁R₁₂, —NR₁₁S(O)₂R₁₂, —NR₁₁S(O)₂NR₁₁R₁₂, —P(O)(OR₁₁)₂, and —NR₁₁P(O)(OR₁₁)₂; R₃ is selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, —CN, —OR₁₁, and —NR₁₁R₁₂; R₄ is selected from the group consisting of —NR₁₁R₁₂, OR₁₁, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; R₁₅ is hydrogen, halo, CN, —NR₁₁R₁₂, —N₃, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl; and R₁₁ and R₁₂ at each occurrence are independently selected from the group consisting of hydrogen, optionally substituted —C₁-C₈ alkyl, optionally substituted —C₂-C₈ alkenyl, optionally substituted —C₂-C₈ alkynyl, optionally substituted —C₃-C₈ cycloalkyl, optionally substituted 3- to 8-membered heterocyclic, optionally substituted aryl and optionally substituted heteroaryl.
 4. A compound selected from the compounds set forth below or a pharmaceutically acceptable salt thereof: Com- pound Structure 1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149


5. A pharmaceutical composition, comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient.
 6. A method of treating or preventing an HBV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a combination of compounds according to claim
 1. 7. The method of claim 6, further comprising administering to the subject at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, literature-described capsid assembly modulator, reverse transcriptase inhibitor, TLR-agonist, inducer of cellular viral RNA sensor, therapeutic vaccine, and agents of distinct or unknown mechanism, and a combination thereof.
 8. The method of claim 7, wherein the compound and the at least one additional therapeutic agent are co-formulated.
 9. The method of claim 7, wherein the compound and the at least one additional therapeutic agent are co-administered.
 10. The method of claim 7, wherein administering the compound allows for administering of the at least one additional therapeutic agent at a lower dose or frequency as compared to the administering of the at least one additional therapeutic agent alone that is required to achieve similar results in prophylactically treating an HBV infection in an individual in need thereof.
 11. The method of claim 7, wherein before administering the therapeutically effective amount of the compound of Formula (I), the individual is known to be refractory to a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, inducer of cellular viral RNA sensor, therapeutic vaccine, antiviral compounds of distinct or unknown mechanism, and combination thereof.
 12. The method of claim 7, wherein the administering of the compound reduces viral load in the individual to a greater extent compared to the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, inducer of cellular viral RNA sensor, therapeutic vaccine, antiviral compounds of distinct or unknown mechanism, and combination thereof.
 13. The method of claim 7, wherein the administering of the compound causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, viral entry inhibitor, viral maturation inhibitor, distinct capsid assembly modulator, inducer of cellular viral RNA sensor, therapeutic vaccine, antiviral compounds of distinct or unknown mechanism, and combination thereof. 